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Abstract 
The reproductive health of women is influenced by microorganisms and their metabolites, 
namely those representing the vaginal microbiota and those producing toxins that are ingested. 
To manipulate the vaginal microbiota toward a health-associated, Lactobacillus-dominant 
state, an approach adopting prebiotic lactulose was taken. Using batch culture, lactulose 
supported Lactobacillus maintenance and positively altered metabolites, while not disrupting 
indigenous L. crispatus epithelial adherence. The vagina also harbours abundant glycogen, but 
initial assumptions that lactobacilli utilize it were incorrect. I have now shown that glycogen 
selectively stimulates organisms associated with dysbiosis and L. iners in a self-limiting 
manner. Other compounds such as environmental toxins have not previously been shown to 
impact vaginal health. In a cohort of Rwandan women, I found that they were indeed exposed 
to fungal toxins. In summary, I have shown that microbes, carbohydrates, and mycotoxins can 
play a significant role in the health of women in Canada and beyond. 
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 Preamble 
Microbes are present everywhere—from our bodies to our environment. Even in tissues 
and body cavities that were previously considered sterile in healthy people, such as breast 
tissue (1) and the upper urinary tract (2), there reside notable communities of bacteria. In 
fact, the number of non-redundant bacterial genes in any individual far outweighs their 
own genetic content (3). Together, the microbes and their genetic potential that populate 
an environment are termed the microbiome (4), while their cumulative secreted metabolic 
by-products are referred to as the metabolome.  
Several hypotheses have arisen to try to explain how specific and distinct bacteria enter 
and populate these sites. Some organisms are transferred from mother to baby during 
development, whether in utero through amniotic fluid (5–7) or the umbilical cord (8), 
during vaginal childbirth (9), or through breast milk (10, 11). Others are acquired from the 
environment through ingestion, inhalation, or direct contact.  
Most of the billions of microbes that humans are exposed to daily are allochthonous, only 
colonizing transiently, while a small proportion reside autochthonously. Dictating this are 
the numerous host and microbial factors that influence their interaction. First, the human 
genome largely influences tolerance to certain microbes (12) because of variants in 
immune responses such as leptin and chemokine signaling, and pattern recognition 
receptors (13). Other host factors include bile acid composition, which bidirectionally 
influences and is modified by gut microbiota (14), and epithelial structure. Regardless, 
resident microorganisms must also possess the necessary machinery to obtain nutrients 
such as carbon and nitrogen from their niche, which varies from site to site. Additionally, 
attachment mechanisms such as adhesin expression, membrane hydrophobicity, and the 
ability to form biofilms can be essential for long-term habitation by microbes. Of course, 
even if all these factors are in place, microbe-microbe competition can also exclude 
organisms from a given site. 
Human health is to a large extent dictated by microorganisms and their products, whether 
it be through pathogen exposure or symbiotic relationships. This has formed the basis of 
the hygiene hypothesis, which underlines the importance of early life contact with a 
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diversity of microbes that shape the immune response, without which allergic diseases have 
become prevalent (15). Furthermore, imbalances of our bodies’ microorganisms influence 
the onset or prevention of many conditions, from irritable bowel syndrome (16), to kidney 
stone formation (17) and anxiety (18). Certain microbial metabolites relate directly to 
disease symptomology, such as the amines secreted by pathogenic microbes to cause odour 
in vaginal dysbiosis (19), or the production of butyrate and its anti-inflammatory effects in 
the gut (20). 
Microbes are especially known to influence women’s health. In breast tissue, a distinct 
microbiota is associated with cancer compared to healthy tissue, possibly due to production 
of DNA damage-causing metabolites (21). Similarly, a woman’s risk for contracting 
sexually transmitted Neisseria gonorrhea or Chlamydia trachomatis infections varies 
depending on the composition of the vaginal microbiota (22, 23). In the case of women 
who become pregnant, microbes are known to influence the pregnancy itself, as well as 
outcomes for the fetus. As an example, miscarriage can be induced by persistent 
colonization with vaginal opportunists (24, 25). Toxins released by food-contaminating 
microorganisms that are consumed by women are also known to have detrimental effects 
on fetal development. For example, zearalenone, a compound secreted by fungi from the 
Fusarium genus and a common food contaminant, mimics estrogen to cause developmental 
delays and death in pregnant rats (26, 27). Although many regulations are in place to limit 
excessive ingestion of such toxic microbial metabolites, little is still known about exposure 
levels in developing nations where food is often scarce, or what the potential negative 
consequences of chronic low dosage are on women’s health. 
Improved techniques for studying bacterial composition and their metabolites have 
provided burgeoning insight into host-microbe interactions. These studies have elucidated 
the tight relationship between microbiome structure and their metabolome, allowing for 
integration of community-function relationships (28). Molecular techniques for measuring 
bacterial populations, such as metagenomics and 16S rRNA sequencing, have increased 
the ability to identify bacteria and their functions, something more difficult using culture-
based methods. These advances have especially broadened the repertoire of organisms 
thought to be present in various sites including the vagina (29), urinary tract (2), and gut 
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(30, 31). Although 16S rRNA sequencing is limited by its inability to observe the genetic 
potential of a bacterial community, and the observed abundances are proportional, this 
technique is effective at monitoring conditions where there are large-scale, defined changes 
to the microbiota. An outstanding example of this is the vaginal microbiome, which is 
dominated by relatively few species in health, and dysbiosis is represented by significantly 
increased diversity and a number of known bacterial genera.  
To gain a better understanding of microbial activity, the use of analytical methods to 
identify metabolic products provides a valuable tool. In comparison to proteomics or 
transcriptomics, metabolomic methods measure all the small molecule metabolites that are 
present in a system. Since these are the end-products of bacterial processes, quantification 
of metabolites is the most accurate reflection of bacterial activity and communication. The 
predominant instruments used are nuclear magnetic resonance (NMR), gas 
chromatography-mass spectrometry (GC-MS), and liquid chromatography-mass 
spectrometry (LC-MS). NMR-based methods provide highly reproducible results, but lack 
sensitivity compared to mass spectrometry. Since gas chromatography is limited to 
measuring compounds that effectively volatilize, liquid chromatography is the most 
valuable tool for measuring low abundance and a broad range of compounds in 
metabolomics experiments. With these novel technologies, huge advances in research on 
the intersection of microbes and women’s health have been achieved. 
 The vaginal microbiome 
In most healthy individuals, the vaginal microbiota is dominated either by Lactobacillus 
iners, L. crispatus, L. jensenii, or L. gasseri (32), with variations in predominance 
depending on several factors. While Caucasian women are more often L. crispatus-
dominant, women of Asian descent are more commonly populated with L. iners (32, 33). 
Circulating estrogen levels also significantly impact the composition of the vaginal 
microbiota. Following menopause, estrogen and Lactobacillus levels in the vagina 
concomitantly decrease (34, 35). Hormone replacement therapy, involving estrogen and 
progesterone administration to reduce unwanted symptoms of menopause, can restore 
Lactobacillus dominance (36). On a smaller scale, estrogen also causes microbiome 
fluctuations throughout the menstrual cycle, with the lowest Lactobacillus levels occurring 
5 
 
during menses (37). This has been linked to glycogen production by vaginal epithelium, 
which is stimulated by elevated estrogen, leading to more abundant carbohydrate sources, 
supposedly for resident lactobacilli (38). 
Not all lactobacilli are considered to equally contribute to a healthy vagina. For example, 
a L. crispatus-dominated microbiota is strongly associated with health, while L. iners is 
found in healthy women and those with bacterial vaginosis (BV). This is supported by the 
findings that L. crispatus-dominant women have more acidic pH (32) and experience less 
instability in microbiota composition (39). On this basis, studies have identified positive 
characteristics of L. crispatus, such as the ability of vaginal secretions from a L. crispatus 
dominant microbiota to kill Escherichia coli (40) and in vitro assays showing inhibition of 
pathogen growth (41). The species has also been shown to confer direct benefits to the host, 
by exerting minimal pro-inflammatory and cell stress responses to the vaginal epithelium 
compared to L. iners (42, 43); promoting thickening of cervicovaginal fluid that better 
defends against HIV-1 (44); and blocking pathogen adherence (45). In contrast, L. iners-
dominated microbiotas tend to have higher pH and are more unstable (32, 39, 46). 
However, recent evidence suggests that L. iners may simply be better suited than L. 
crispatus to adapt to the varied conditions of the vaginal environment, allowing it to persist 
throughout dysbiosis and antibiotic therapy (47, 48). 
1.2.1 Protective mechanisms of vaginal lactobacilli 
Vaginal lactobacilli possess a vast repertoire of functions that are thought to impart their 
dominance in this niche. Many lactobacilli produce antimicrobial compounds such as 
hydrogen peroxide (H2O2), lactic acid, and bacteriocins (49). Early in vitro studies 
emphasized H2O2 as a major defense mechanism of lactobacilli due to its ability to kill 
Gardnerella vaginalis and sequester HIV-1 through the H2O2-peroxidase-halide pathway 
(50, 51), leading to the screening of vaginal probiotics on the basis of H2O2 production 
(52). However, the validity of this has come into question since H2O2 is ineffective in 
vaginal conditions, namely oxygen-depletion and acidic pH below 4.5, and it can also be 
toxic to lactobacilli (50, 53, 54). Furthermore, the activity of H2O2 is sequestered by the 
proteinaceous environment imparted by male ejaculate and vaginal secretions (55). Given 
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this, the biological impact of H2O2 in exerting Lactobacillus dominance is no longer seen 
as well founded. 
The greatest body of evidence exists for lactic acid fermentation as the primary defense for 
vaginal lactobacilli. By definition, lactobacilli are fermentative and release lactic acid as a 
metabolic by-product, giving the vaginal ecosystem a distinctly acidic pH that is not 
tolerated by many pathogens (56, 57). Both acidic pH (<4.5) and elevated lactic acid in 
cervicovaginal fluid are strongly associated with health, and the former is often used 
diagnostically (19, 56, 58). O’Hanlon et al. (57) demonstrated physiological concentrations 
of lactate in healthy women at 1.0% (w/v), which is a sufficient concentration to kill 
common pathogenic bacteria, but not lactobacilli (53, 59). Lactic acid acts through 
disruption of the membrane of Gram-negatives (60) to kill organisms associated with 
vaginal dysbiosis (53), and it is also directly viricidal to HIV-1 (59). In addition, lactic acid 
influences the host’s response to pathogens, where physiological levels induce an anti-
inflammatory immune response in vaginal epithelial cells (61) that limits the potential for 
HIV acquisition (62). Ultimately, extensive research on lactic acid has clarified the need 
for this Lactobacillus metabolite and acidic pH for vaginal health. 
Vaginal lactobacilli have also been observed to secrete bacteriocins, a structurally diverse 
group of antimicrobial peptides that target physiologically similar microbes to the 
producer. Bacteriocin activity against the dysbiotic organism G. vaginalis has been 
reported by many vaginal lactobacilli (49, 63, 64), including predominant species L. 
gasseri, L. jensenii, and L. vaginalis. Further characterization of bacteriocin gene clusters 
has been performed on L. crispatus and L. gasseri strains, revealing their encoded 
gassericins (64) and putatively identified bacteriocins with similarity to helveticin J and 
enterolysin A (65). Antimicrobial proteins are also secreted by exogenous probiotic 
lactobacilli, such as the soluble antimicrobials found in L. rhamnosus GR-1 supernatant 
(66). This has implicated bacteriocins as an alternative treatment for dysbiosis of the vagina 
as their activity is specific to disease-associated strains and not lactobacilli. Unfortunately, 
pathogenic G. vaginalis strains have already developed resistance against various 
bacteriocins (48, 62), and antibiotic-resistant strains are even more likely to have 
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bacteriocin resistance (68). Since the in vivo effect of these bacteriocins on the bacterial 
composition in the vagina is still unknown, further studies are needed to assess their impact. 
Biofilm formation is a major virulence factor in a variety of human pathogens. It relies 
initially on bacterial adherence to a surface, followed by secretion of exopolysaccharides 
and other factors, to form a structure that protects contained bacteria from invading 
microbes and antibiotics (69). Although vaginal biofilms are often considered a 
characteristic of pathogens such as G. vaginalis and Atopobium vaginae (70), lactobacilli 
can also utilize biofilms to maintain dominance in this niche (71). Furthermore, 
Lactobacillus-derived biosurfactants can disrupt pathogenic biofilms and change epithelial 
cell surface tension to make it less receptive to pathogen adherence (72, 73). Combined 
with the observation that adherent vaginal lactobacilli (74) utilize surface glycoproteins 
and saccharides to displace Candida albicans and G. vaginalis from epithelial glycolipids 
(66, 75, 76), adherence and biofilm production are major beneficial characteristics of 
lactobacilli.  
Nonetheless, when pathogenic colonization persists, Lactobacillus adhesion can still 
contribute to the removal of invaders through coaggregation (67). This is initiated by the 
adhesion of bacteria to one another, and it is frequently observed between urogenital 
species (77, 78). Notably, vaginal lactobacilli adhere strongly to pathogenic 
Staphylococcus aureus to displace it from the ecosystem (79). However, this system works 
both ways, as bacterial coaggregation also dislodges Lactobacillus spp. from the vaginal 
epithelia. Thus, strains being considered as candidate probiotics are screened for 
aggregative properties, with a view that administering them will release adherent pathogens 
from native lactobacilli (78). In support of this, probiotic L. reuteri RC-14 was observed to 
have stronger adhesion to S. aureus than common indigenous lactobacilli (79) and has been 
shown to incorporate into pathogen biofilms and subsequently kill encapsulated pathogens 
(80). 
1.2.2 Bacterial vaginosis 
Despite abundant antimicrobial mechanisms innate to vaginal lactobacilli, nearly one in 
three women experience a microbial imbalance of the vagina referred to as BV (81). A 
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recent review has critiqued the terminology surrounding BV, whereby it appears to 
encompass several inflammatory and non-inflammatory phenotypes (Reid, 2017). In the 
currently accepted, non-inflammatory form of the condition, lactobacilli are outgrown by 
pathogenic anaerobes, especially Prevotella, Atopobium, Mobiluncus, and Gardnerella 
species (82). Around 80% of BV-positive women are asymptomatic (81) and not treated, 
and it is thought that up to one quarter without symptoms have latent BV, characterized by 
a vaginal microbiome consisting of these diverse fastidious anaerobes (32). This explains 
why so many undetected cases appear in such studies of so-called “healthy” women, 
thereby limiting physicians’ ability to best manage these individuals. It also adds confusion 
because symptoms are derived from bacterial metabolites that are not directly related to the 
target therapy.  
The emergence of new and diverse pathogens in BV chemically modifies the vaginal 
environment compared to healthy women. Lactic acid production by lactobacilli is reduced 
so pH rises above 4.5, and pathogens upregulate enzymes whose activities release short-
chain fatty acids (SCFAs) such as succinate, acetate, and butyrate (19, 83, 84). For this 
reason, a succinate:lactate ratio of >0.4 has been used as a marker for BV. But this method 
lacks sensitivity (80%) and specificity (83%) (85), possibly because L. crispatus also 
produces succinate (19). McMillan et al. (80) utilized mass spectrometry to improve 
detection of metabolic markers of BV, and in doing so, identified 2-hydroxyisovalerate (2-
HV) and γ-hydroxybutyrate (GHB). Improved diagnostic capabilities are possible by using 
2-HV:tyrosine ratios (sensitivity of 89% and specificity of 94%), which also eliminates the 
need for normalizing to sample weight (19). Another BV-specific SCFA, butyrate, reduces 
gut inflammation and could be acting similarly to prevent inflammation in BV (86), 
potentially limiting the ability to sense the condition. Several BV-associated species and 
genera such as P. amnii, Dialister, Mobiluncus, Prevotella, Megasphaera, and 
Mycoplasma (83, 84) also produce amines (putrescine, cadaverine, and spermidine) 
responsible for the “fishy odour” of symptomatic BV (58). Overall, chemical changes in 
BV are responsible for many characteristic symptoms and signs, and certain profiles have 
the potential to improve diagnostic techniques for identifying overgrowth of pathogenic 
anaerobes. 
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Historically, two methods have been the standard for BV diagnosis: Amsel criteria and 
Nugent scoring. Under the former, clinical diagnosis requires at least three of four Amsel 
criteria: Elevated pH, creamy discharge, malodor, and the presence of “clue cells”—
vaginal epithelial cells coated with short, Gram-variable rods (58). The Nugent scoring 
technique is widely adopted for laboratory diagnoses of BV, and uses Gram-staining 
methods to score Lactobacillus-dominated (0 to 3), intermediate (4 to 6), and BV organism 
dominated (7 to 10) microbiotas (87). Gram-stain based methods appear to more accurately 
detect dysbiosis associated with BV (84), as they rely on an observer to note Lactobacillus 
reduction in place of pathogenic bacteria. However, bacteria can take on many shapes and 
sizes, so the reliability of a Gram stain is questionable. Other laboratory techniques such 
as 16S rRNA sequencing of the V6 or V4 regions (88) are more effective in identifying 
BV organisms, and specific microarrays have been developed on this basis (89). As the 
cost of molecular techniques reduce, it is hoped that these sensitive and more effective 
‘omics’ methods will reach standard clinical diagnostic settings.  
Despite the lack of apparent symptoms and signs in most cases, BV increases the risk for 
additional infections and adverse reproductive health. Numerous studies in pregnancy have 
reported associations with preterm labour and low birth weight, with BV patients at a 1.4–
6.8 times greater risk of giving birth prematurely (90–92). In the first trimester of 
pregnancy, BV also doubles the risk for miscarriage in otherwise healthy individuals (24). 
Though it is unknown exactly how this occurs, speculation has been on upper genital tract 
inflammation due to bacterial colonization. This is somewhat surprising considering that 
BV is a relatively non-inflammatory condition lower in the vagina. A study by Hillier et 
al. (93) demonstrated that, among the 61% of premature births with bacterial colonization 
of the chorion and amnion, the most commonly infecting pathogens were BV-associated 
bacteria Ureaplasma urealyticum and G. vaginalis. Furthermore, BV organisms penetrate 
and infect amniotic fluid (23). Their subsequent release of virulence factors such as 
sialidase (91), mucinase (91), and endotoxins (94) may induce inflammatory cytokines (94, 
95) to trigger premature delivery and spontaneous abortion (96). However, additional 
investigations are needed to fully elucidate the mechanism of the labour response in these 
women. 
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BV conditions can also reduce the presence of health-promoting lactobacilli, increasing 
susceptibility to sexually transmitted bacterial and viral infections. Comorbidity with BV 
increases viral load (97), shedding (98), and contraction (99) of HIV-1, leading to a 3-fold 
increased risk for transmitting the virus to male partners (100). Enhanced susceptibility of 
BV-affected women to contracting HIV-1 might be explained by the influx of CCR5+ T 
cells to the vagina (101), the cellular target for HIV (102). Upregulated interleukin-1β from 
BV infection may also enhance the transcriptional activity of HIV, further exacerbating the 
infection (103). Thus, the overall mechanism by which BV-infected women become 
susceptible to adverse HIV outcomes is multifaceted and still poorly understood. 
Lactobacilli help the host defend against Neisseria gonorrhoeae (22, 99), Chlamydia 
trachomatis (22), pelvic inflammatory disease (104), and cervicitis (105), but this is lost 
during BV onset. In addition, BV is strongly associated with Trichomonas vaginalis (99) 
and herpes simplex virus 2 (HSV-2) (106) infections, though HSV-2 is likely the cause of 
BV co-occurrence rather than the result (107). One potentially confounding issue in these 
associations is that there are shared risk factors between STI and BV contraction and 
unfortunately it is difficult to ascertain which variables are responsible. 
Given the complications associated with BV, researchers have directed their efforts toward 
identifying its risk factors. Many otherwise dangerous sexual behaviours like having 
multiple partners, group sex, and sexual abuse are correlated with BV (108, 109), but 
condom and hormonal contraceptive use are protective (110, 111). As BV is a condition 
and not an infection by any single organism, it has not been considered a sexually-
transmitted disease. However, BV bacteria may be transmitted directly by women having 
sex with women (112, 113). Other sources of these microbes may provide external 
reservoirs for BV organisms, such as those found in urine (114), anal and oral cavity (115), 
or partner’s penile microbiota (116), potentially leading to persistent re-colonization. 
The treatment of BV typically involves a 7-day regimen of either oral or local 
metronidazole or oral clindamycin (117). Both drugs quickly deplete pathogenic anaerobes 
in the vagina, with early efficacy as high as 94-96% (118–120), yet BV organisms often 
recover once the antibiotic regimen ceases (119, 121). Thus, BV recurrences are common, 
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being 20% after one month (120) and as high as 58% one year after metronidazole 
treatment (121). Risk behaviours for relapse include having a consistent sexual partner 
throughout treatment and sex with women (121), which supports a mechanism where 
infected women recirculate BV organisms between their partner and themselves. 
Gardnerella vaginalis is also highly adaptive against metronidazole, considering its many 
antibiotic-resistant strains (68) and rapid recolonization after treatment (119). Bacterial 
biofilms of G. vaginalis and A. vaginae contribute to bacterial resistance in BV, and are 
present in 90% of cases (69, 70, 122). Since G. vaginalis is the most effective primary 
colonizer of vaginal surfaces (123), it is thought that its initial attachment paves the way 
for additional pathogens to adhere (124). Finally, some researchers attribute antibiotic 
failure to collateral damage to native lactobacilli (125), since neither metronidazole nor 
clindamycin promote recovery of indigenous lactobacilli. Regardless, there is clearly a 
need for alternative treatment methods, particularly those that treat BV as a dysbiotic 
condition that requires restoration of lactobacilli, rather than an infection. 
1.2.3 The potential for vaginal probiotics and prebiotics 
There has already been a great deal of promise for BV treatment using natural remedies 
such as probiotics, as these focus on the replenishment of health-associated vaginal 
lactobacilli. The United Nations/World Health Organization defines probiotics as “live 
microorganisms, which when administered in adequate amounts, confer a health benefit on 
the host” (126). Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 are the most 
documented for use in treating and preventing BV, especially since they persist for some 
time in the vagina (127). In several studies, oral supplementation of GR-1 and RC-14 in 
conjunction with oral metronidazole improved Lactobacillus restoration in BV-affected 
women by 10–39% (128–130). This was not recapitulated in a separate cohort of HIV-
positive women, suggesting that intact immunity is still required for recovery (131). 
Alternatively, prebiotics, defined as “substrates that are selectively utilized by host 
microorganisms conferring a health benefit” (132, 133), have been adopted to increase the 
proportion and activity of lactobacilli in other microbiotas (133, 134). Lactobacilli in the 
vagina are also feasible targets for prebiotic stimulation, however, few studies have been 
performed to this end. Compounds such as lactoferrin, not a traditional prebiotic, were 
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found to prevent BV onset and its associated negative reproductive outcomes in a woman 
with recurrent miscarriages (92). Lactoferrin is an antimicrobial compound found in bodily 
fluids and is not fermented by vaginal bacteria. Other researchers have demonstrated the 
potential for various fructo-oligosaccharides (FOS) and gluco-oligosaccharides (GOS). 
Rousseau et al. (135) isolated vaginal lactobacilli and tested these and pathogens (C. 
albicans, E. coli, and G. vaginalis) against several FOS and GOS compounds, finding that 
only lactobacilli were stimulated by FOS Actilight® and α-1,6/α-1,4 GOS. A locally 
administered gel formulation containing these α-1,6/α-1,4 GOS prebiotics improved 
Nugent scores following metronidazole treatment of BV (136). However, key experiments 
are still required to determine which prebiotics safely stimulate lactobacilli growth without 
also stimulating BV organisms and other pathogens, as well as produce metabolic activity 
associated with a healthy vagina.  
 Fungal toxins and women’s health 
Unlike probiotics and prebiotics, other microbes and microbial products can have serious 
detrimental effects to the health of women. Much research has been dedicated to the 
consequences of fungal colonization in a woman’s own ‘mycobiome’, particularly due to 
the reported 75% incidence of vulvovaginitis in women, caused by yeasts from the genus 
Candida (137). However, contamination of food by fungi can also result in the ingestion 
of toxic products. Of these, mycotoxins are of particular concern due to their extremely 
high prevalence, known serious adverse health effects, and inability to be detoxified by 
regular cooking practices. Mycotoxins are secondary metabolites secreted by various 
Aspergillus, Fusarium, and Penicillium spp., which commonly contaminate crops destined 
for animal or human consumption. The World Health Organization outlined major 
mycotoxins of concern in humans in a 1999 bulletin, which included the classes aflatoxins, 
ochratoxins, zearalenone, and fumonisins (138). In general, the effects of mycotoxin 
exposure can be delineated by mycotoxicosis, or acute exposure, and chronic long-term 
effects, of which there is much less research. 
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1.3.1 Aflatoxins (AF) 
The most thoroughly documented mycotoxins belong to a group called aflatoxins, which 
are produced by Aspergillus fungi. Specifically, aflatoxin B1 and B2 are secreted by 
Aspergillus flavus and A. parasiticus, and G1 and G2 only by A. parasiticus. These molds 
contaminate nuts and seeds (139), especially peanuts, and cereals such as maize, millet and 
wheat. Aflatoxin production is induced in a wide range of environmental conditions, but 
most favourably in humid climates with consistent temperatures above 24°C (140). Thus, 
the effective management of aflatoxin production involves fungicide application (141), 
drying of crops, storage in refrigerated conditions, and frequent testing. In the US, these 
extensive measures result in an estimated $52.1 million – $1.68 billion cost to the corn 
industry alone (142). 
Of the different aflatoxins, B1 is one of the most carcinogenic compounds known to humans 
(143), due to its bioactivation during metabolism into a DNA-reactive epoxide. Upon 
ingestion and absorption, AFB1 is metabolized by detoxification enzymes in the liver, 
namely cytochrome P450 (CYP) 3A4 and 1A2 (144). Oxidation can result in two major 
products, the exo and endo isomers, of which the former is a highly genotoxic compound 
and the latter is sequestered. While CYP1A2 metabolism can produce either metabolite, 
most aflatoxins are degraded by CYP3A4 preferentially into the bioactivated exo-epoxide. 
CYP1A2 can also detoxify AFB1 into AFM1, a metabolite which is subsequently excreted 
in urine and is a sensitive biomarker for short-term AFB1 exposure. Conversely, the highly 
reactive structure of AFB1-exo-epoxide conjugates DNA and forms an adduct with 
guanine, which results in consistent mutations during DNA replication. Since most of this 
reactive product is produced in the liver, this is the primary target for mutation, and causes 
the associated high risks for liver cancer in exposed populations. In addition, AFB1-exo-
epoxide may also react with positively-charged lysine residues in circulating albumin. This 
adduct represents another sensitive biomarker for AFB1 ingestion, but due to the long half-
life of albumin, reveals longer-term exposure. 
Toxicity due to acute high doses of aflatoxin is termed aflatoxicosis, which often presents 
as liver failure. Most cases of aflatoxin exposure are chronic low dose, which leads to liver 
cancer, as described above, as well as developmental delays and growth stunting in children 
14 
 
(145). Recently, aflatoxin B1 was associated with more circulating virus in people infected 
with HIV, suggesting an immuno-suppressant effect (146). 
Due to the globalization of food, aflatoxin exposure occurs pretty much worldwide, 
including non-tropical climates; however, countries in Africa appear to be disparately 
affected. Even in Kenya, where a serious outbreak of aflatoxicosis in 2004 resulted in over 
200 deaths, contamination still occurs because of failures to implement adequate safety 
procedures (147). Reports of AFB1 across Africa have shown that exposure is common in 
women. Levels of the plasma albumin adduct biomarker in women from Kenya, Ghana, 
and Egypt were a median of 5.0, 7.47, and 4.9 pg/mg albumin, respectively (148–150), 
while urinary AFM1 was found at a median level of 162 and 19.7 pg/mg creatinine in 
Zimbabwean and Egyptian women (150, 151). AFM1 can also be passed to infants through 
breastfeeding, with African mothers’ breast milk concentrations ranging from 4.2–497 
pg/mL (152, 153). 
No studies, to date, have measured aflatoxin exposure levels in Rwandan populations, but 
food contamination appears to be widespread in this country. The European Commission 
(EC) and US Food and Drug Administration (FDA) regulations for total aflatoxins in food 
are 4–10 and 20 ppb, respectively, and the EU also specifies a limit of 2–8 ppb for AFB1. 
Observations of aflatoxin contamination above these regulatory limits in Rwandan maize 
flour have frequently occurred (154–156), as well as lower quantities in cassava (156, 157). 
Given the mass popularity of maize and cassava consumption in Rwanda, this population 
is at elevated risk for AFB1 toxic effects and further work must address this. 
1.3.2 Fumonisins (F) 
Fumonisins B1 and B2 are mycotoxins produced by Fusarium spp., namely Fusarium 
verticillioides, previously known as F. moniliforme (158). F. verticillioides has the highest 
expression of FB1 and FB2 in humid conditions and suboptimal growth temperatures of 
20°C and 20–30°C, respectively (159). Under these conditions, FB1 and FB2 have been 
commonly associated with improper handling of maize and cereals, such as wheat and 
millet. Short-term acute exposure to fumonisins causes a form of mycotoxicosis 
characterized by diarrhea and stomach cramping (160), while chronic intake in adults has 
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been associated with esophageal (161) and liver cancer (162). Furthermore, exposure in 
pregnant women is associated with developmental defects in their fetus, namely neural tube 
defects (163). 
The toxicity of these compounds has been traced mainly to their ability to replicate the 
structure of cellular sphingosine and sphinganine. Both FB1 and FB2 bind the active site of 
enzymes required for the degradation of these sphingolipids, thereby preventing their 
catalysis and causing cellular accumulation. Since increased levels of sphingolipids are 
thought to reduce folate uptake in utero, and folate depletion increases risks for neural tube 
defects, this has been proposed as a mechanism of teratogenicity by fumonisins (164). 
However, there has been no correlation observed between cancer incidence and elevated 
sphingolipids (165), suggesting that there may be other mechanisms directing fumonisin’s 
carcinogenic effects, such as induction of apoptosis or increased reactive oxygen species 
(166). 
In humans, measured urinary levels of FB1 and FB2 represent validated biomarkers for 
exposure (167). Urinary FB1 is typically found in significantly greater abundance than FB2, 
reflecting similar proportions in contaminated crops. For example, in adult cohorts from 
South Africa, Cameroon, and Nigeria, reported urinary FB1 concentrations were 470–1520 
pg/mg creatinine, 330 pg/mg creatinine, and 4.6 ng/L (167–170), while the same 
Cameroonian and Nigerian individuals had FB2 concentrations below the limit of 
quantification and at 1.0 ng/L, respectively (169, 170). One country whose population 
which has been neglected in human exposure studies has been Rwanda, where elevated 
FB1 and some FB2 have been found in numerous food sources. Average detectable levels 
of FB1 in Rwandan maize flour and cassava are similar, and range from 21.9–31.1 µg/kg, 
and for FB2 are slightly lower at 10.1–17.0 µg/kg (156, 157). FB1 was also found to 
contaminate banana beers brewed in Rwanda at a consistent level around 32 µg/kg (171). 
Although these are below the limits set by the EC and US FDA, which are 200–1000 ppb 
and 2000–4000 ppb, respectively, elevated concentrations could still be acquired from 
consuming these products in excess and the detriments of chronic low doses are still 
applicable. 
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1.3.3 Zearalenone (ZEN) 
Zearalenone (ZEN), sometimes referred to as F-2 toxin, is a heat-stable mycotoxin that is 
also predominantly produced by the Fusarium fungi, making it a popular contaminant of 
cereals and grains. Like fumonisins, ZEN is secreted differentially by various species of 
Fusarium, and in greatest amounts in a warm, damp climate (172). Its negative effects, 
particularly for females, are due to its ability to act as an estrogen agonist, mediated by its 
structural similarities to the hormone (173). Thus, women with elevated ZEN are at greater 
risk for breast cancer (174, 175) and in pregnant women, fetal abnormalities may develop 
(27). 
Human exposure to ZEN across African nations appears to be particularly prevalent. In 
several studies quantifying ZEN in Cameroon and South Africa, this compound was 
present in nearly all individuals, with the average urinary concentrations at 210 and 529 
pg/mg creatinine, respectively (168, 169). In Rwanda, zearalenone is among one of the 
most commonly found mycotoxins in cassava, contaminating nearly 50% of this popular 
crop (157), though it was absent in another study of cassava flours (156). Beer brewed in 
Rwanda also reportedly contains 0.66-2.2 µg ZEN/kg (171). With the widespread and 
abundant contamination of crops with ZEN, as well as its clear influence on women’s 
health, additional studies are essential for understanding its impact in women in the 
developing world. 
1.3.4 Ochratoxin A (OTA) 
Ochratoxin A (OTA) contamination of food is perhaps the most widespread of all 
mycotoxins. This toxin is secreted by Aspergillus ochraceus, A. carbonarius, and 
Penicillium verrucosum into a variety of foods including coffee (176), grapes, and various 
grains. Its ingestion from these crops is often associated with various kidney diseases (177), 
including Balkan endemic nephropathy; however, research on the mechanism of this 
pathogenicity is limited to animals and correlative studies (178). With the seriousness of 
multiple other mycotoxins in African countries, as described above, OTA was not 
historically considered a major threat to human health. However, several studies have 
reported OTA commonly in Africa, such as in Cameroon, South Africa, and Nigeria where 
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urinary levels were 70 pg/mg creatinine, 41 pg/mg creatinine, and 0.2 µg/L, respectively 
(168, 169). Specifically in Rwanda, both cassava and peanut crops are reportedly 
contaminated with OTA at levels above the regulatory limits (156, 157). Considering the 
disparity between the lack of research in Rwanda and other nations in Africa, and the 
apparent prevalence of OTA contamination, there warrants additional studies in this area. 
 Rationale and Specific Aims 
1.4.1 Rationale 
Microorganisms and their metabolites significantly influence the health of females, with 
an outcome of health or disease being mediated by the genetic capabilities of the species 
present. The vaginal microbiota is shaped by several host factors, including carbohydrates, 
and it can either support vaginal homeostasis through the production of antimicrobial and 
anti-inflammatory lactic acid (62, 179), or form an environment conducive to pathogen 
infiltration (22). The healthy state is characteristic of a Lactobacillus-dominated vaginal 
microbiota, while the latter represents a form of dysbiosis currently termed BV, whereby 
bacterial diversity increases and lactobacilli and vaginal acidity are depleted (19, 32, 180). 
Treatment of this condition, typically a regimen of antibiotic metronidazole, is often 
ineffective at restoring vaginal lactobacilli and results in high rates of BV recurrence (121, 
181). Thus, prophylactics and treatments are necessary to prevent remission and treat BV, 
but the ultimate goal should be to recover and enhance native lactobacilli and their 
beneficial properties. 
The mono-culture methods that are utilized to evaluate interventions to the vaginal 
microbiota, and the animal models used prior to human trials are unsatisfactory to 
recapitulate the complexity of bacterial interactions in the vaginal microbiota that direct 
responses to a new carbohydrate source (182). The vaginal environment is not naturally 
devoid of sugars that might themselves contribute to microbial homeostasis. In particular, 
glycogen, released by vaginal epithelium, has long been thought to preferentially 
supplement lactobacilli due to a strong correlation between the two (34). Given its 
abundance, yet lack of studies demonstrating its metabolism by many of the most common 
vaginal bacteria, glycogen’s role in shaping the vaginal microbiota remains to be 
18 
 
determined. I hypothesize that carbohydrate sources, both intrinsic and external to the 
vaginal environment, can be manipulated to favour Lactobacillus dominance and activity 
in the vagina. 
The negative impact of microbial products can also derive from sources external to the 
female microbiota. Mycotoxins are heat-stable compounds secreted mainly by Aspergillus, 
Fusarium, and Penicillium molds that have a range of carcinogenic, teratogenic, and toxic 
effects (138). Foods from countries in the developing world, such as Rwanda, are 
disparately contaminated with mycotoxins because the warm, humid climate is conducive 
to fungal growth, and there is limited information about how to recognize and prevent 
exposure. Though several studies have identified aflatoxins, fumonisins, ochratoxin A, and 
zearalenone in Rwandan crops (154–157), the biological exposure and toxic effects in 
women are still unknown, despite them being the predominant cultivators in Rwanda (183). 
I hypothesize that urine and blood mycotoxins will reflect levels in contaminated foods in 
Rwanda, and higher exposure will correlate with adverse health outcomes in women. 
1.4.2 Aim 1: Evaluate lactulose, and a panel of prebiotics, for their ability to 
selectively stimulate vaginal lactobacilli and improve the metabolic 
profile 
In studies on the gut microbiota, the ability of unique compounds to selectively stimulate 
lactobacilli and other beneficial organisms has been adopted with significant success (184). 
These compounds, called prebiotics, modulate the composition and activity of the 
microbiota toward a state that benefits the health of the host (132). In the vagina, dysbiosis 
is extremely common and involves significant reductions in the Lactobacillus population 
and disruptions to the metabolic profile. Several studies have evaluated prebiotics for 
stimulating lactobacilli in the vaginal microbiota to prevent or treat BV; however, none 
have examined their effects on the microbiota as a unit, or their metabolites (92, 135, 136, 
185). As microbial products are the cause of malodour, inflammation, and other symptoms 
in vaginal dysbiosis (19, 186), they must be measured alongside evaluations of vaginal 
prebiotics. 
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In Chapter 2 of this thesis, I develop an effective polymicrobial batch culturing model to 
evaluate the potential of lactulose as a vaginal prebiotic, to stimulate lactobacilli, restore 
acidity, and reduce markers of BV. 
1.4.3 Aim 2: Examine additional mechanisms through which lactulose 
improves the beneficial properties of vaginal epithelium and 
Lactobacillus crispatus 
The consensus definition for prebiotics was recently expanded to encompass a broader 
repertoire of compounds, potential active sites, as well as their mechanism of action (132). 
Importantly, one must consider the impact prebiotics have on bacterial-bacterial 
interactions, as well as the host tissues they contact. Since Lactobacillus crispatus is most 
associated with feminine health, additional implications for its stimulation by prebiotics 
should be considered (32, 39). We previously observed that vaginal Lactobacillus crispatus 
strains ubiquitously fermented lactulose, resulting in significant pH decline and elevated 
lactic acid production. However, additional properties of lactulose stimulation may alter 
properties of the vaginal microbiota and host. To benefit the microbial ecosystem, lactulose 
should impart an advantage to L. crispatus against organisms involved in dysbiosis, which 
may be mediated by acid production, or secretion of the putatively identified antimicrobial 
peptide (bacteriocin) present in its genome (65). Conversely, integrating sugars into a new 
environment can disrupt polysaccharide-dependent attachment interactions between L. 
crispatus and the vaginal epithelium (187). Before taken into human trials, lactulose must 
also be tested for antagonistic effects on the vaginal epithelium, as its integrity is essential 
for vaginal health. 
Therefore, Chapter 3 will address these additional properties and the effect lactulose has 
on bacterial and host interactions. 
1.4.4 Aim 3: Evaluate how glycogen influences the growth and activity of 
vaginal microbes 
Glycogen, a highly branched oligosaccharide consisting of glucose monomers, is the major 
carbohydrate source available in the female genital tract, and therefore an important 
component in shaping the resident microbiota. It is freed in large abundance from vaginal 
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epithelial cells, particularly when elevated estrogen levels stimulate its production (188). 
Initially, glycogen was thought to supplement vaginal lactobacilli because of the 
association between high glycogen levels, a Lactobacillus-dominant microbiota, and an 
acidic vaginal pH (34, 188, 189). However, most commonly dominant species such as L. 
crispatus, L. jensenii, and L. gasseri, as well as L. plantarum, have been observed to not 
utilize glycogen (190). This paradigm was seemingly resolved with the discovery that 
human α-amylases are also released into vaginal fluid from the epithelia, where they can 
metabolize glycogen into component sugars that are fermented by lactobacilli (191). 
However, these metabolites, mostly glucose and maltose, are almost ubiquitously utilized 
by bacteria and would not specifically benefit lactobacilli. Upon comparison of the vaginal 
transcriptome during health and BV, Macklaim et al. (83) observed that bacterial α-
amylases are upregulated when lactobacilli are in low abundance and that these genes 
originate from BV-associated bacteria. Furthermore, the L. iners dominated microbiota has 
higher α-amylase activity than the L. crispatus dominated microbiota (43). It is reasonable 
to postulate then, that glycogen may stimulate the growth of unwanted BV organisms rather 
than the previously considered lactobacilli.  
In Chapter 4, I therefore directly evaluate the glycogen fermentative capacity of vaginal 
lactobacilli and BV isolates, and its influence on the interaction between microbiota 
members. 
1.4.5 Aim 4: Report on exposure levels of important mycotoxins to address 
how they may influence risk to women’s health in Rwanda 
Mycotoxins are a serious concern for human health, especially in the developing world 
where an estimated 4.5 billion people are repetitively exposed (192). Acute exposure to 
these compounds results in mycotoxicosis, while chronic low doses have been linked to 
liver and kidney damage, cancer, growth stunting, and adverse fetal development (138). 
As weaker regulations on crops exist in developing countries and their climate is conducive 
to fungal growth, contamination with mycotoxins in these countries remains consistently 
high. Despite several studies observing aflatoxin, fumonisin, ochratoxin A, and 
zearalenone contamination in Rwandan crops (154–157), few studies have reported on the 
human exposure levels. As women represent both the primary contact to farmlands (183) 
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and targets for many of the health effects, specifically related to infant health, their 
exposure to these mycotoxins is important to quantify. 
In Chapter 5, I report the development of a urinary multi-mycotoxin method using LC-
MS/MS and measured biomarkers in a high-risk cohort of Rwandan women, and determine 
their impact on fertility and general health outcomes.  
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Chapter 2  
 
Evaluation of prebiotics for maintenance and restoration of a 
Lactobacillus-dominated vaginal microbiota establishes lactulose 
as a promising candidate 
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2018. Promising prebiotic candidate established by evaluation of lactitol, lactulose, 
raffinose, and oligofructose for maintenance of a Lactobacillus-dominated vaginal 
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 Abstract 
Perturbations to the vaginal microbiota can lead to dysbiosis, including bacterial vaginosis 
(BV), which affects a large portion of the female population. In a healthy state, the vaginal 
microbiota is represented by low diversity and colonization by Lactobacillus spp., whereas 
in BV, these species are displaced by a highly diverse population of bacteria associated 
with adverse health outcomes. Since prebiotic ingestion has been a highly effective 
approach to invigorate lactobacilli for improved intestinal health, we hypothesized that 
these compounds could stimulate lactobacilli at the expense of BV organisms to support 
vaginal health. Monocultures of commensal Lactobacillus crispatus, L. vaginalis, L. 
gasseri, L. johnsonii, L. jensenii, and L. iners in addition to BV-associated organisms and 
Candida albicans were tested for their ability to utilize a representative group of prebiotics: 
lactitol, lactulose, raffinose and oligofructose. The disaccharide lactulose was found to 
most broadly and specifically stimulate vaginal lactobacilli, including the strongly health-
associated L. crispatus, and importantly, not BV organisms or C. albicans. Using batch 
cultured vaginal samples, we showed that exposure to lactulose promoted Lactobacillus 
maintenance in healthy samples, but not restoration from dysbiosis. Regardless of initial 
health status, lactulose stimulated healthy acidity through lactic acid production, while 
suppressing malodor-associated putrescine and cadaverine. This provides support for 
further testing of lactulose to prevent dysbiosis, and potentially reduce the need for 
antimicrobial agents in managing vaginal health. 
 Introduction 
In most healthy reproductive-age women, Lactobacillus spp. are the main constituents of 
the vaginal microbiota. Their ability to acidify this niche through lactic acid production 
(193), and otherwise beneficially modulate the environment (194), is profoundly important 
for female health and reproduction (195). However, in a condition known as bacterial 
vaginosis (BV), anaerobes such as Gardnerella vaginalis, Atopobium vaginae, Prevotella 
spp., and Mobiluncus spp. proliferate, sometimes causing aberrant symptoms and signs 
(89, 180). These organisms displace Lactobacillus spp., causing an elevation in vaginal pH 
and predisposing women to pelvic inflammatory disease, HIV-1 transmission, and 
infection by Trichomonas, Chlamydia trachomatis and Neisseria gonorrhoeae (22, 99, 
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104). Recurrent BV patients also have higher rates of vulvovaginal candidiasis, caused by 
overgrowth of the opportunistic Candida albicans (196). The condition is extremely 
common, with a reported prevalence of 30% in the United States (81), leading to a 
significant burden to both women and the health care system (197). 
In recent years, researchers have identified metabolic changes that provide insight into BV 
symptomatology and a basis for novel detection methods. Lactic acid, produced as a 
metabolic by-product mainly by Lactobacillus spp., has long been understood to pose 
health benefits by acidifying the vagina (56, 57) and limiting pathogen viability (53, 59, 
60). Thus, its absence has been associated with diversity and BV (19). One of several 
diagnostic criteria for BV includes odour presentation (58), which has been linked to 
biogenic amine production, namely putrescine and cadaverine (19, 84, 186, 198), by BV-
associated Dialister spp. and Prevotella and Porphyromonas spp., respectively (84). 
Conversely, tyrosine levels are reduced in BV, likely because of their use as precursors for 
amine production (19, 198). Amine detection has been taken into spectrometry-based 
diagnostics for BV with some success (199), though there may be better alternatives. 
McMillan et al. (19) showed that gamma-hydroxybutyrate (GHB) was a reproducible, 
sensitive, and selective biomarker for BV and traced its origins to G. vaginalis, a common 
microbe associated with dysbiosis. Together, these reflect overall modifications of the 
metabolic profile during BV onset that are important in understanding its pathogenesis. 
The treatment for BV has for decades been administration of metronidazole or clindamycin 
targeting anaerobes. However, in addition to side effects and failure to restore microbiota 
homeostasis, large numbers of women fail to respond or relapse within months of treatment 
(121, 200). While some women maintain a stable vaginal microbiota, most show 
fluctuating patterns due to antimicrobial agents, menstruation, and sexual activity, as well 
as unknown factors (39). Too often, restoration of a Lactobacillus-dominant microbiota 
does not occur. This has led to interventions containing probiotic therapies, such as L. 
reuteri RC-14 and L. rhamnosus GR-1, which help the indigenous lactobacilli recover 
(128–130). 
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Another approach worth considering is the use of a prebiotic, defined as a substrate that is 
selectively used by beneficial host microorganisms to confer a health benefit (132). These 
are generally food-grade compounds including inulin and other fructo-oligosaccharides 
(FOS), sugar alcohols, galacto-oligosaccharides (GOS), lactulose, and raffinose. They are 
known to stimulate native bifidobacteria and lactobacilli in the intestine, leading to a range 
of favourable gastrointestinal outcomes including reduced inflammation (201). The 
concept of using selective nutrients to supplement vaginal microbes was first introduced 
by our group in 1995, where we showed that skim milk improved vaginal Lactobacillus 
numbers in women with recurrent urinary tract infections (202). Several prebiotics have 
since been evaluated for their efficacy in stimulating vaginal lactobacilli both in vitro and 
in small human trials, including GOS (135, 136), FOS (135, 203), and glucomannan 
hydrolysates (185, 204). The assessment of these and other formulations, however, has 
been based on testing against single strains or characterizing dysbiosis using combinations 
of culture- and microscopy-based techniques, which lack the sensitivity needed to detect 
the numerous low abundance anaerobes present in BV. For example, organisms denoted 
BVAB1-3 have been deemed critical for BV onset and pathogenesis, yet have been 
unculturable to date (115, 205, 206). Instead, molecular techniques such as 16S rRNA 
sequencing and metabolomics (used in this study) should be adopted to accurately observe 
modifications to the vaginal microbiota and metabolome. 
Therefore, the objective of the present study was to develop a method for testing the effects 
of prebiotic compounds against a range of biologically relevant vaginal lactobacilli and 
bacteria associated with dysbiosis, and to apply 16S sequencing and mass spectrometry-
based targeted metabolomics to assess their impact. 
 Results 
2.3.1 Fermentation profiles of prebiotics by vaginal microbes 
Following bacterial culture in 0.5% prebiotic-supplemented, dextrose-free media, pH was 
measured post-incubation to indicate whether prebiotics were fermented and if this process 
could restore acidity, an essential component of vaginal health. Lactulose increased the 
maximal growth of L. crispatus (p<0.0001), L. gasseri (p<0.05), L. vaginalis (p<0.01), and 
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L. jensenii RC-28 (p<0.0001) compared to no prebiotic media (Figure 2.1). Lactulose 
treatment also correspondingly lowered the pH compared to no prebiotic media for L. 
crispatus (p<0.001) and L. jensenii RC-28 (p<0.001) (Figure 2.1). Since a L. crispatus-
dominated vaginal microbiota is most strongly correlated to positive health outcomes (25, 
40), and strains of the same species can vary greatly in their ability to degrade sugars, the 
metabolism of lactulose by fifteen clinical L. crispatus isolates was demonstrated (Figure 
2.2). Although lactulose did not significantly elevate the viable counts of L. iners (p=0.50), 
the pH was lowered compared to no prebiotic media (p<0.01) (Figure 2.1). This suggests 
that L. iners produces fermentation products upon lactulose inoculation, despite not 
growing. Lactulose limited the growth of C. albicans (p<0.001) and A. vaginae (p<0.05) 
compared to media without prebiotic, while not affecting the growth of G. vaginalis, P. 
bivia, or M. curtisii (Figure 2.2). Overall, lactulose was broadly and effectively used by 
vaginal Lactobacillus spp., while not stimulating potential pathogens. 
Oligofructose, raffinose and lactitol were less preferred than lactulose by vaginal 
lactobacilli in culture. Oligofructose improved the growth of L. gasseri (p<0.001) and L. 
jensenii 25258 (p<0.0001) compared to no prebiotic control, though acidic pH was only 
reached by L. jensenii 25258 (p<0.001) (Figure 2.1). However, oligofructose antagonized 
L. iners (p<0.01) (Figure 2.1) and attenuated the growth of C. albicans compared to no 
prebiotic media (p<0.0001) (Figure 2.3A). Raffinose elevated the maximal growth of L. 
crispatus (p<0.0001), L. gasseri (p<0.05), and L. vaginalis (p<0.01), causing media 
acidification in L. vaginalis culture only (p<0.05) (Figure 2.1). Conversely, raffinose also 
lowered L. iners viability compared to media without prebiotic (p<0.01) (Figure 2.1). 
Although lactitol only stimulated L. crispatus growth (p<0.0001), acidic products were 
produced by both lactitol-inoculated L. crispatus (p<0.001) and L. jensenii RC-28 (p<0.05) 
(Figure 2.1). Furthermore, lactitol reduced C. albicans density relative to no prebiotic 
media (p<0.0001) (Figure 2.3A). No notable growth of G. vaginalis, A. vaginae, M. 
curtisii, or P. bivia was observed in oligofructose, raffinose, or lactitol (Figure 2.3B). 
2.3.2 Bacterial composition of vaginal samples incubated with prebiotics 
Having established that lactulose most effectively stimulated Lactobacillus spp. in 
monoculture, we developed a method to culture the community of vaginal microbiota from 
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Figure 2.1: Growth and pH of vaginal lactobacilli cultured in prebiotics 
Individual cultures of vaginal lactobacilli inoculated in 0.5% prebiotic media prior to pH 
testing. For growth curves, points represent mean (OD600) or geometric mean (CFU/mL) 
of 3-7 replicates ± SEM, with differences determined using 2-way ANOVA with Dunnett’s 
multiple comparisons test. For pH measurements, bar heights are mean pH ± SD, with 
differences to control determined using Kruskall-Wallis’ with Dunn’s multiple 
comparisons tests. 
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Figure 2.2: Lactulose is ubiquitously utilized by vaginal L. crispatus clinical isolates 
Individual cultures of vaginal L. crispatus isolates obtained from women with or without 
BV were inoculated in dextrose-free MRS supplemented with 0.5% (w/v) lactulose. Points 
represent the mean OD600 ± SD. 
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Figure 2.3: Growth and pH of C. albicans and BV organisms cultured in prebiotics 
 (A) C. albicans supplemented with 5% prebiotic. (B) BV-associated bacteria inoculated 
in 0.5% prebiotic media prior to pH testing. For growth curves, points represent mean 
(OD600) or geometric mean (CFU/mL) of 3-7 replicates ± SEM, with differences 
determined using 2-way ANOVA with Dunnett’s multiple comparisons test. For pH 
measurements, bar heights are mean pH ± SD, with differences to control determined using 
Kruskall-Wallis’ with Dunn’s multiple comparisons tests. 
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swabs collected from healthy women. These were then inoculated in media containing 
0.5% prebiotic, or control media without prebiotic. Initially, all four healthy swabs were 
dominated by Lactobacillus spp., with those from Subjects 1, 3, and 4 mostly composed of 
L. crispatus, and Subject 2 mostly with L. iners (Figure 2.4). The microbial community of 
each subject reacted variably to prebiotic treatment. Notably, each prebiotic appeared to 
improve the resilience of lactobacilli. In Sample 1, lactobacilli increased in abundance in 
each prebiotic relative to control media by 48 hours (Figure 2.4). Lactulose particularly 
maintained Lactobacillus dominance, as noted by its restoration to above 90% abundance 
by 48 hours (Figure 2.4). In Sample 2, lactulose, as well as lactitol and raffinose, improved 
Lactobacillus maintenance, while oligofructose supplementation caused a relative 
abundance shift toward Staphylococcus spp. compared to the no-prebiotic control (Figure 
2.4). Sample 3 microbiota responded similarly to treatment with lactulose, lactitol, and 
oligofructose, with early time-points showing elevated Lactobacillus abundance compared 
to control before 48 hours post-inoculation (Figure 2.4). Raffinose supplementation, on 
the other hand, improved Lactobacillus abundance throughout 48 hours (Figure 2.4). Only 
lactitol induced prolonged maintenance of Lactobacillus spp. in Sample 4, compared to no-
prebiotic media and lactulose, raffinose, and oligofructose supplementation (Figure 2.4). 
To elucidate whether these proportional changes were due to increased numbers of 
beneficial lactobacilli, rather than a loss of aerobic organisms, we next used qPCR for total 
Lactobacillus numbers. Lactulose treatment increased Lactobacillus abundance by 48 
hours in L. crispatus-dominant Samples 1, 3, and 4, and in early time-points for Sample 2 
(Figure 2.5A). Oligofructose consistently stimulated lactobacilli, increasing its abundance 
in all four swabs after 48 hours; though the mean change was not significant (p=0.2388) 
(Figure 2.5A). Raffinose slightly increased total lactobacilli after 48 hours in Samples 1 
and 3, while decreasing their numbers in Samples 2 and 4 compared to no-prebiotic media 
(Figure 2.5A). Lactitol increased Lactobacillus levels in Samples 1 and 4, while decreasing 
them in 2 and 3 (Figure 2.5A). 
Since BV-related organisms were in low relative abundance and therefore were not 
observable in the context of the whole microbiota, their abundances, as a centered-log ratio, 
were monitored individually. Notably, none of the detectable BV-associated organisms  
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Figure 2.4: Swab microbiota dynamics throughout inoculation in prebiotics 
Vaginal swab microbiota from four separate donors were cultured in dextrose-free 
vaginally-defined medium with 0.5% (w/v) prebiotic. Bar heights represent the fraction of 
the microbiota taken up by each genus at the designated sampling point, as determined by 
16S rRNA sequencing of the V4 region. 
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Figure 2.5: Growth of lactobacilli and M. curtisii in prebiotic-supplemented vaginal 
swab microbiota 
Concentration of (A) Lactobacillus spp., and (B) M. curtisii 16S rDNA from vaginal swab 
microbiota grown in 0.5% prebiotic. Points are individual measures of growth for each 
individual swab, and are the geometric mean ± SEM for the average of all swabs. 
Geometric means were analyzed for significant differences using two-way ANOVA with 
Dunnett’s multiple comparisons test. 
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present in the swab communities were stimulated by prebiotic treatment (Figure 2.6). Two 
commonly characterized BV organisms, A. vaginae and M. curtisii, were not proportionally 
abundant enough to be identified by sequencing, so absolute quantification qPCR was 
adopted to specifically target these bacteria. In further support of its absence, A. vaginae 
was not detected with this technique (Data not shown). M. curtisii levels were elevated to 
the greatest extent by lactitol and oligofructose in Samples 1 and 4, though neither reached 
significance overall (Figure 2.5B). 
2.3.3 Metabolite changes in prebiotic-cultured healthy vaginal swab 
communities 
Several other important indicators of vaginal health include acidity and metabolites from 
actively fermenting commensal lactobacilli (53, 57). To determine whether acidity could 
be restored by prebiotic treatment in the healthy vaginal microbiota model, swab samples 
were pH tested following 48 hours of incubation with the prebiotics. Lactulose was found 
to significantly lower the pH (p<0.05), a phenomenon not observed with any other prebiotic 
(Figure 2.7A). Since in vivo vaginal acidification in healthy women is predominantly due 
to lactate production by lactobacilli (56), LC-MS quantification of this metabolite was 
performed. After 48 hours, lactulose and oligofructose increased lactate production in the 
cultures of Samples 1, 2 and 4 compared to no-prebiotic media, but only increased lactate 
at early time points in Sample 3 (Figure 2.7B). Lactitol also increased lactate abundance 
in Samples 2, 3, and 4, while raffinose lowered media lactate compared to no-prebiotic 
control in Samples 1, 2, and 3 (Figure 2.7B). 
To confirm that prebiotic utilization by bacteria in the human samples was the cause of 
media acidification and lactate production, GC-MS of spent media was used to detect levels 
of prebiotics following incubation. Both lactulose (p<0.05) and lactitol (p<0.01) were 
significantly lowered in the media following 48 hours of swab bacterial growth. 
Conversely, raffinose levels remained static (Figure 2.8), indicating that changes caused 
by raffinose treatment were not due to bacterial metabolism of this prebiotic. 
Oligofructose’s highly polymerized and variable structure prevented accurate detection of 
this prebiotic, and therefore it was eliminated from this analysis.  
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Figure 2.6: Abundance of various BV-associated organisms from healthy vaginal 
swab consortia grown in prebiotics 
Mean centered log-ratios ± SD of BV-associated bacterial OTUs from 16S rRNA 
sequencing of the V4 region. Samples were taken throughout growth of batch cultured 
healthy swab bacteria in 0.5% (w/v) prebiotic or no prebiotic control. There were no 
significant differences (p>0.05) in proportional abundance between any prebiotic treatment 
and control media, according to two-way ANOVA with Dunnett’s multiple comparisons 
test (n=4). 
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Figure 2.7: Metabolic analysis of healthy vaginal swab consortia in prebiotics 
 (A) Mean pH ± SD of swab communities following 48 hours of growth in prebiotics. 
Statistical significance determined according to the Kruskall-Wallis test with Dunn’s 
multiple comparisons (*p<0.05). (B) Peak area of LC-MS-detected lactate, log2 corrected, 
in swab bacterial supernatant. Dots are individual measures of growth over time. 
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Figure 2.8: Abundance of lactitol, lactulose, and raffinose following healthy vaginal 
swab consortia growth 
Peak area of GC-MS-detected prebiotics, log2 transformed, in swab bacterial supernatant 
before addition of bacteria (media) and after 48 hours of growth. Mean quantities are 
significantly different from baseline, according to the one-sample t-test (*p<0.05, 
**p<0.01). 
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Since GHB and 2-hydroxyisovalerate are specific biomarkers of BV, and cadaverine, 
putrescine, and tyramine are responsible for vaginal odor (19, 84), we measured these 
metabolites in healthy vaginal samples inoculated with prebiotics, but did not detect them 
in any growth condition (Data not shown). 
2.3.4 Lactulose does not restore a Lactobacillus-dominated vaginal 
microbiota in an in vitro co-culturing model of dysbiosis 
Nugent scoring of swabs upon collection identified samples DES123, NVP548, RAC123, 
SAO123, SHA966, and XYZ456 as BV positive, and samples 999ZZZ, ALT519, CUB452, 
and LIS123 as intermediate. Using 16S rRNA sequencing of the V4 region, changes to the 
bacterial composition of batch-cultured swabs upon lactulose treatment were monitored. 
For samples ALT519, DES123, and NVP548, there were few, if any, differences in the 
bacterial profile of lactulose-treated and control swab consortia (Figure 2.9). Swabs 
999ZZZ, CUB452, SHA966, an XYZ456 inoculated with lactulose were nearly dominated 
by Streptococcus by 48 hours, at the expense of Proteus, Escherichia coli, 
Finegoldia/Gardnerella vaginalis, and Peptostreptococcus/Proteus/Dialister in the 
respective controls (Figure 2.9). Despite a transient shift to Streptococcus at 24 hours, the 
population in swab LIS123 shifted almost entirely to L. crispatus in lactulose-treated media 
by 48 hours, while its control counterpart retained greater diversity and a population 
consisting of Porphyromonas, L. jensenii, and L. crispatus (Figure 2.9). Control- and 
lactulose-treated sample RAC123 achieved similar diversity at 48 hours, though some of 
the genera were dissimilar, including increased Streptococcus and Sutterella and decreased 
Parvimonas and Howardella spp. with lactulose treatment (Figure 2.9). Lastly, lactulose-
supplemented SAO123 had a much lower proportion of undefined Lactobacillus spp. after 
24 and 48 hours, and increased relative abundance of Streptococcus, E. coli, and Proteus 
(Figure 2.9). 
To narrow down the impact of lactulose on Lactobacillus abundance within the swab 
consortia, CLRs of OTUs representing predominant lactobacilli were plotted over time. 
Overall, lactulose had no significant impact on the three major species detected (L. 
crispatus, L. iners, and L. jensenii), though a slight trend toward increased total  
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Figure 2.9: 16S rRNA microbiota composition of aberrant vaginal consortia 
inoculated with 1% (w/v) lactulose 
Bacterial collected from vaginal swabs of 10 separate donors with an intermediate or BV-
associated Nugent score were cultured in dextrose-free vaginally-defined medium with 1% 
(w/v) lactulose (Lac) or no prebiotic (Ctrl). Bar heights represent the fraction of the 
microbiota taken up by each genus at the designated sampling point, as determined by 16S 
rRNA sequencing of the V4 region. 
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Lactobacillus was observed (Figure 2.10). Multivariate analyses of the aberrant 
microbiotas in lactulose and control media did not detect any overarching community 
differences in the two treatment groups (Data not shown). 
2.3.5 Lactulose-induced metabolic changes of dysbiotic vaginal swab 
microbiota. 
As in the previous exploration of prebiotic effects on the healthy vaginal metabolic profile, 
pH and metabolites associated with BV were quantified throughout aberrant swab 
inoculation in lactulose. Following 48 hours of growth in lactulose, the overall mean pH 
of BV positive and intermediate swab batch cultures was lowered significantly compared 
to control (p<0.01, Figure 2.11A). This response was bimodal, with four samples having 
substantially lowered pH compared to others, corresponding to samples CUB452, LIS123, 
RAC123, and SHA966 (Figure 2.11A). Apart from LIS123, these samples were related in 
that their Streptococcus population was elevated by 48 hours in lactulose (Figure 2.9). In 
contrast, lactulose-treated LIS123 was nearly dominated by Lactobacillus crispatus, 
compared to approximately 10% abundance in control (Fig. 2.9). Lastly, acidic response 
was not directly related to the patient’s original Nugent score (Figure 2.11A). Upon 
measuring levels of common acidic bacterial metabolites in the vaginal microbiota, a 
significantly elevated (p<0.001) concentration of lactic acid was observed in the media 
following 48 hours of aberrant swab inoculation (Figure 2.11B). 
Several additional metabolites of importance, apart from acids, were quantified throughout 
the growth period. Surprisingly, lactulose was not depleted from the media after 24 hours 
or 48 hours of bacterial growth (p>0.05, Figure 2.12A). There were also no differences in 
tyrosine production or consumption during the incubation period (p>0.05, Figure 2.12B), 
and gamma-hydroxybutyrate was not detected in any sample (Data not shown). However, 
lactulose treatment significantly lowered secretion of putrescine (p<0.001) and cadaverine 
(p<0.05) (Figure 2.12C). 
  
45 
 
 
Figure 2.10: Mean abundance of Lactobacillus spp. in aberrant swab microbiotas 
treated with lactulose 
Mean centered log-ratios of 16S rRNA sequences representing total Lactobacillus, L. 
crispatus, L. iners, and L. jensenii from swab batch cultures grown in dextrose-free VDMP 
± 1% (w/v) lactulose. Genus and species were identified by comparison to the Silva 
reference database. Lactobacillus abundance was only included if read counts were greater 
than blank 16S extractions. Points represent mean abundance ± SD (n=10). Significance 
between control and lactulose treatment at each time point was determined using two-way 
RM ANOVA with Sidak's multiple comparisons test (p>0.05). 
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Figure 2.11: Treatment with lactulose triggers acid production by aberrant vaginal 
swab microbiotas in vitro 
Acidic characteristics of aberrant swab microbiotas throughout growth in 1% (w/v) 
lactulose-supplemented or control dextrose-free VDMP. Following growth, (A) Mean pH 
± SD of supernatants were measured. Significance was determined using Kruskall-Wallis 
with Dunn’s multiple comparisons test (*p<0.05). Points are coloured according to the 
Nugent score of the associated swab. (B) Concentration (in µg/mL) of lactic and succinic 
acids in supernatants at various time points, determined using targeted LC-MS with 
external standards. Significant differences between lactulose-treated and control media at 
each time point were determined using two-way RM ANOVA with Sidak’s multiple 
comparisons test (***p<0.001). 
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Figure 2.12: Levels of lactulose, tyrosine, and production of odor-associated BV 
metabolites by aberrant vaginal swab microbes 
Metabolic characteristics of aberrant swab microbiotas throughout growth in 1% (w/v) 
lactulose-supplemented (●) or control (●) dextrose-free VDMP were determined using 
targeted LC-MS with external standards. Points represent concentration (in µg/mL) of (A) 
lactulose, (B) tyrosine, and (C) odor-associated amines in each supernatant at the indicated 
time following inoculation. Significant reductions in lactulose from initial measurement 
were determined using one-way ANOVA with Dunnett’s multiple comparisons test 
(p>0.05), while differences in tyrosine and amine concentrations between lactulose-treated 
and control media at each time point were determined using two-way RM ANOVA with 
Sidak’s multiple comparisons test (*p<0.05, ***p<0.001). 
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 Discussion 
Herein we have characterized a candidate prebiotic, lactulose, for its ability to promote 
microbial and metabolic homeostasis in healthy and dysbiotic vaginal microbiota models, 
independent of antibiotic use. We showed that supplementation of bacterial monocultures 
with lactulose stimulated L. gasseri, L. vaginalis, L. jensenii RC-28 and 16 strains of L. 
crispatus, while antagonizing C. albicans and A. vaginae. Additionally, although lactulose 
did not improve the viability of L. iners, the drastically lowered media pH suggests that it 
was fermented by L. iners. These initial experiments indicate that lactulose selectively 
propagates a range of commensals and not vaginal pathogens. In a healthy model, lactulose 
promoted maintenance of a Lactobacillus-dominated community and production of acidic 
metabolites, namely lactate. Despite its inability to restore lactobacilli in a similar in vitro 
model of dysbiosis, lactulose again effectively increased overall lactate secretion and 
acidity, while also lowering levels of vaginal odor-associated putrescine and cadaverine. 
Variation in the positive, Lactobacillus-stimulating response by lactulose between the 
healthy and aberrant swab models likely reflects difficulty lactobacilli experienced in 
outcompeting a whole community of bacteria and the challenges associated with finding a 
completely selective prebiotic. As we are taking the community from a likely homeostatic 
state and delivering fresh nutrients, initial bacterial abundance will weigh greatly on its 
ability to outcompete other organisms. Despite the apparent preference of lactulose for 
lactobacilli, both models showed a notable proportion of aerobes, especially Streptococcus 
in the aberrant population, that gained dominance. There are very few studies that have 
monitored vaginally-relevant aerobic microbes’ growth in lactulose since this is the first 
case utilizing it for vaginal health; however, others have shown stimulation of oral and 
enteric Streptococcus spp. by lactulose (208–210). Weakening this argument is the 
observation that lactulose was not spent from the media inoculated with aberrant 
microbiotas, suggesting that it is not consumed by these bacteria. Furthermore, since these 
organisms are often not colonizers of the vaginal niche and are likely only present due to 
unavoidable exposure to aerobic conditions, this may not reflect in vivo efficacy of the 
tested compounds. Regardless, further considerations might be of benefit prior to taking 
this into humans. A greater understanding for the lactulose-metabolizing potential of the 
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dysbiotic vaginal microbiome, perhaps through uncovering specific enzymes required for 
its degradation and analyzing the transcriptome in health and disease for such genes (83), 
might better predict its efficacy in humans. 
Across both healthy and dysbiotic in vitro models, lactulose induced beneficial changes to 
the metabolic profile. Its pH-lowering effect is largely attributable to increased secretion 
of lactic acid, the predominant fermentation metabolite of lactobacilli. Importantly, lactic 
acid and low pH are indicative of vaginal health and inhibit the development of BV, HIV-
1 infectivity, and other dysbioses (53, 59, 60). Lactulose has also been reported to rapidly 
increase media acidity in non-vaginal Lactobacillus cultures (211, 212), suggesting that it 
might provide a broad and immediate advantage to acid-tolerant, commensal lactobacilli 
over pathogens. In our model of dysbiosis, lactulose significantly attenuated putrescine and 
cadaverine production, amines that are associated with vaginal microbiota diversity (186, 
199) and BV-related malodor (19, 84, 198). More recently, these metabolites have been 
observed to enhance pathogen biofilm formation (213), an important component of BV 
pathogenesis and antibiotic resistance (122, 124, 214). As lactulose is not digested in the 
simulated aberrant microbiotas, the mechanism of action might be through inhibition of 
lysine and ornithine decarboxylases, the major enzymes responsible for cadaverine and 
putrescine synthesis in vaginal microbes (186). However, without controlled studies this is 
largely speculative. Considering its beneficial effects on the bacterial metabolome, 
lactulose is well founded for use as a vaginal prebiotic. 
Of the other prebiotic compounds assessed, lactitol was also fermented by vaginal 
lactobacilli in monoculture and increased the proportional abundance of Lactobacillus spp. 
in the vaginal sample consortium. However, despite an increase in media lactate, this 
compound did not restore an acidic pH. This suggests that the quantity of lactate produced 
by the lactitol-treated consortium was not sufficient to lower media pH. In practice, lactitol 
could be administered with pH-lowering reagents in a two-pronged approach, a concept 
that has been taken into product development but not yet evaluated. Lactitol administered 
with lactobacilli following clindamycin treatment has been shown to improve recovery 
from BV (215), but the role of lactitol alone was not delineated, leaving questions about its 
contribution to this therapy. 
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In culture, raffinose was fermented by several Lactobacillus strains, but it appeared to 
antagonize L. iners, a common vaginal commensal found in women with and without BV 
(46, 193). Although raffinose positively altered the composition of the vaginal swab 
consortium, it did not directly stimulate lactobacilli. This suggests that raffinose inhibits 
the growth of bacteria such as Staphylococcus or Enterococcus spp., thereby allowing 
commensal lactobacilli to propagate. This is further supported by the lack of fermentation 
products produced and high levels of raffinose remaining in the spent media of the vaginal 
sample. However, other researchers have also observed that raffinose can be used by 
Trichomonas vaginalis (216), the vaginal parasite responsible for trichomoniasis, further 
underscoring its unsuitability as a vaginal health agent. 
Oligofructose was utilized by L. gasseri and L. jensenii 25258 in our study, and L. 
acidophilus in a previous investigation (203). However, despite its Lactobacillus-
stimulating properties in our vaginal microbiota model, oligofructose did not increase the 
proportion of lactobacilli, and it antagonized L. iners AB-1 in culture. Oligofructose also 
stimulated growth of C. albicans, the causative agent of vulvovaginal candidiasis, and did 
not acidify the swab sample despite doing this in mono-culture. Since polymerized 
oligosaccharides such as oligofructose tend to be fermented slower and to a lesser degree 
than short oligosaccharides (217), it may have taken longer than the allotted 48 hours to 
produce sufficient metabolic products to lower the pH. It is important to note that the 
retention time of prebiotics in the vagina is likely much shorter than colonic transit time 
and therefore quick-releasing effects would be optimal for this niche. Others have observed 
that FOS with lower degrees of polymerization than oligofructose are used by vaginal 
Lactobacillus isolates and not C. albicans or G. vaginalis (135), thus this does not rule out 
the potential for all oligosaccharides in vaginal application. However, only a single strain 
of each lactobacilli was tested in monoculture in these studies, so their effect on a complex 
culture system remains to be investigated. For the reasons stated above, our results suggest 
against the use of oligofructose for vaginal health. 
The model developed herein for studying the effects of prebiotics on the vaginal microbiota 
uses the organisms already active within the vaginal ecosystem of each subject. Although 
less reproducible than a defined steady-state culture, utilizing samples taken from 
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numerous donors allows improved insight into the breadth of responses that could be 
observed in vaginal microbiota interventions. As we observed here, despite genus-level 
similarities in microbiota composition, the selective nature of prebiotics exerts variable 
effects on bacterial proportions because of differences in bacterial expression of 
carbohydrate metabolism genes, even at the strain level (218, 219). As any candidate 
intervention must eventually be applicable to women, a method that more closely predicts 
diversity in responses has merit. Ultimately, lactulose must be taken into a randomized 
clinical trial to prove its functionality in humans.  
In summary, we have demonstrated that lactulose stimulates vaginal lactobacilli, but not 
common dysbiotic organisms, promotes a healthy acidic environment, and limits the 
production of BV odor-associated metabolites. Confirmation in this novel human model 
provides a basis for further exploration of lactulose as a vaginal prophylactic. We have 
observed the greatest benefit for maintenance of a eubiotic microbiota, which is broadly 
applicable due to the frequent microbial fluctuations women experience throughout the 
menstrual cycle (37) and from sexual activity (109, 113). As a treatment for dysbiosis, 
lactulose may be valuable in conjunction with antibiotics or more Lactobacillus-
stimulating therapeutics because of its positive effects on pH and the metabolic profile. 
Another forthcoming potential application may include conditioning an individual’s own 
aberrant microbiota ex vivo with lactulose for beneficial reintroduction into the vagina, a 
concept that has been coined TripleA therapy (220). Ultimately, this inexpensive 
compound may reduce the necessity for antibiotics, including their side effects and inability 
to prevent dysbiotic recurrences. 
 Materials and Methods 
2.5.1 Strains, growth conditions, and prebiotics used 
Vaginal Lactobacillus strains (L. crispatus ATCC 33820T, L. vaginalis NCFB 2810, L. 
gasseri ATCC 33323T, L. jensenii RC-28 and L. jensenii ATCC 25258) and L. johnsonii 
ATCC 20553 were cultured on MRS agar (Becton, Dickinson & Company, Sparks, MD) 
anaerobically in jars at 37°C. L. iners AB-1 and BV-associated bacteria Gardnerella 
vaginalis ATCC 14018, Atopobium vaginae ATCC BAA-55, Prevotella bivia ATCC 
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29303, and Mobiluncus curtisii ATCC 35241 were cultured on Columbia Agar with 5% 
sheep’s blood (CBA) (Becton, Dickinson & Company) anaerobically at 37°C in a 
controlled chamber (80% N2, 10% CO2, 10% H2). Candida albicans TIMM 1768 was 
aerobically cultured on Lysogeny Broth (LB) agar at 37°C. Prebiotics selected were lactitol 
monohydrate (Alfa Aesar, Ward Hill, MA), lactulose (Alfa Aesar), D (+)-raffinose (Sigma, 
St. Louis, MO), and Orafti P95 oligofructose (Beneo, Oreye, Belgium). 
OD600 measurements were taken for Lactobacillus growth curves, excluding L. iners, in 
dextrose-free MRS with 0.5% (w/v) prebiotic using the MultiSkan Ascent (Thermo-Fisher, 
Waltham, MA). Due to their inability to be cultured in a microaerophilic environment, 
growth of L. iners, G. vaginalis, A. vaginae, P. bivia, and M. curtisii was monitored using 
drop plating in an anaerobic chamber (80% N2, 10% CO2, 10% H2) in dextrose-free New 
York City (NYC) III broth with 0.5% prebiotic. Growth was determined by comparison to 
control media without dextrose. Once the growth media was spent, cultures were subjected 
to pH fermentation testing (VWR International, Radnor, PA). C. albicans viability in 
dextrose-free Tryptic Soy Broth (TSB) with 5% prebiotic was measured by optical density 
during constant aerobic agitation at 37°C. 
2.5.2 Confirmatory analysis of clinical L. crispatus strains 
The clinical L. crispatus strains were isolated from vaginal swabs used to remove abundant 
mucus during routine cervical examinations at the sexually transmitted infections (STI) 
clinic in Amsterdam, the Netherlands. These swabs, which are normally discarded, were 
collected in June and July 2012 and immediately placed in transport media with additional 
15% glycerol and stored at -80°C. As visitors to the STI clinic were informed that their 
samples may be used for scientific research after anonymization and no extra clinical 
procedure was performed, no official approval under the Dutch Medical Research 
Involving Human Subjects Act (WMO) was required (reference number W12_86 # 
12.17.0104). For this study, vaginal swabs from women with or without BV, according to 
the Nugent score, were plated on TSB agar supplemented with 5% serum and 0.25% lactic 
acid and pH set to 5.5 and grown under micro-aerobic conditions (6% O2) for 2-3 days 
(221). L. crispatus strains were identified based on colony morphology and their 16S rRNA 
sequence. To measure growth in lactulose, L. crispatus strains were inoculated, as above, 
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in dextrose-free MRS supplemented with 0.5% (w/v) lactulose, and OD600 measurements 
were taken every 30 min for 24 hours. 
2.5.3 Healthy subjects and vaginal swab collection 
Four healthy premenopausal women (aged 25 to 30) volunteered for the study, approved 
by the Health Sciences Research Ethics Board at Western University (HSREB#106089, 
Appendix A.1). After signing informed consent, women self-swabbed the lateral vaginal 
walls five times using separate sterile Dacron® swabs. A healthy vaginal pH <4.5 was 
confirmed by participants using pHem-Alert® applicator keys (Gynex Corporation, 
Redmond, WA). Confirmation of healthy status was performed by smearing a swab on a 
microscopic slide and Gram staining (Becton, Dickinson & Company), and scored 
according to the Nugent system (87). Subjects were included only if a normal Nugent score 
of 0-3 was observed, indicating the presence of large Gram-positive rods. Independent 
swabs were used for initial microbiota analysis and assessment of prebiotic effects over 
time. 
2.5.4 Incubation of healthy vaginal samples in prebiotics 
Each vaginal swab was placed in 1 mL of PBS and vortexed for 5 min to release the bacteria 
and cellular contents. The liquid was then equally distributed into dextrose-free Vaginally-
Defined Media + Peptone (VDMP) (222) with or without 0.5% (w/v) lactitol, lactulose, 
raffinose, or oligofructose. Individual time points and prebiotic growth conditions had 
separately designated tubes. Growth of swab bacteria was performed in anaerobic jars at 
37°C until designated time points, when tubes were centrifuged for 10 min at 21 000 × g 
to separate cells from media. The pellet was subjected to microbiome analysis (see below), 
and supernatant assessed for metabolites by mass spectrometry, and for acidification using 
pH 2.0-9.0 test strips (VWR). 
2.5.5 Non-healthy subjects and vaginal swab collection 
Ethics approval for collection of vaginal swabs was obtained (HSREB#106089, Appendix 
A.1). Ten pre-menopausal women (aged 18 to 55) were recruited at Victoria Family 
Medical Centre in London, Canada. After signing informed consent, vaginal swabs were 
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obtained by a medical professional in addition to routine cervical examinations. 
Immediately upon collection, swabs were placed in liquid Amies media as a part of the 
ESwab™ anaerobic transport system (Copan Diagnostics Inc., Murietta, CA) and 
processed in the laboratory. A second swab was obtained to determine health status of the 
microbiota using the Nugent scoring system. 
2.5.6 Incubation of non-healthy vaginal samples in lactulose 
Vaginal swabs suspended in liquid Amies media were vortexed on low for 5 min to extract 
bacterial cells. The liquid was then equally distributed into pre-reduced dextrose-free 
VDMP with or without 1% (w/v) lactulose. Growth of swab bacteria was performed in an 
anaerobic chamber (80% N2, 10% H2, 10% CO2) at 37°C until 24 and 48 hours post-
inoculation, when separate designated tubes were removed. Cells were separated from 
supernatant by centrifugation for 10 min at 21 000 × g and stored separately at -80°C. The 
pellet was subjected to microbiome analysis (see below), and supernatant assessed for 
metabolites by mass spectrometry, and for acidification using pH 2.0-9.0 test strips (VWR). 
2.5.7 Microbiota analysis by 16S rRNA sequencing 
2.5.7.1 DNA extraction 
Microbial DNA was extracted from swab microbiota using the Powersoil®-htp 96-Well 
Soil DNA Isolation Kit (Mo Bio Laboratories, Carlsbad, CA), according to the 
manufacturer’s instructions. 
2.5.7.2 PCR amplification and sequencing 
The V4 variable regions of 16S ribosomal RNA were amplified in a PCR reaction 
containing 50 µL light mineral oil, 1 µL sample DNA, and 10 µL each of barcoded primers 
at 3.2 pMol/uL, which together were set to 85°C before adding 20 µL of GoTaq master 
mix (Promega, Madison, WI). Reactions were primed at 95°C for 3 min, followed by 25 
cycles of 95°C for 1 min, 52°C for 1 min, and 72°C for 1 min. Samples, media blanks, 
extraction blanks, and amplification blanks, were subsequently prepared and sequenced at 
the London Regional Genomics Centre (lrgc.ca, London, Ontario, Canada). First, DNA 
was quantified using a Qubit 2.0 Fluorometer (Thermo-Fisher), pooled at an equal volume 
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of each sample, and purified using the QIAquick PCR Purification kit (Qiagen, Hilden, 
Germany). Purified amplicons were then paired-end sequenced with 250 cycles on an 
Illumina MiSeq (San Diego, CA) in 5% Phi X. 
2.5.7.3 Data analysis 
The protocol for initial processing of reads was adapted from the dada2 workflow by Dr. 
Greg Gloor (github.com/ggloor/miseq_bin), using the “dada2” and “ShortRead” packages 
in R version 3.2.2 (r-project.org). Read quality was determined by plotting quality profiles 
for both the forward and reverse reads. Filtering was performed based upon quality profiles 
and reads were trimmed to the expected length of 183 and 174 for V4 with paired-end 
2x250 cycle sequencing using 12-mer barcodes. Dereplication was performed to 
summarize individual sequence units (ISUs) by abundance in each sample. Reads derived 
from PCR or sequencing errors were detected and removed using joint sample inference 
and error rate estimation on dereplicated ISUs. Pairs of forward and reverse reads were 
then overlapped and merged into complete sequences. By summarizing overlapping 
sequences by length, outliers were removed: five 200 bp sequences, one 201 bp sequence, 
and two 209 bp sequences were identified and removed, leaving only sequences of 238-
240 bp. Chimeric sequences were also identified and removed. The final output of 139 
sequences at this stage can be found at DOI:10.6084/m9.figshare.4657192 (figshare.com). 
Taxonomy was generated to the genus level by comparison of best hits to the Silva rRNA 
database v123, and to the species level, where possible, according to the Silva species 
assignment database v123 (www.arb-silva.de/silva-license-information). Taxonomy was 
designated when sequences matched the species with 100% identity and there were no 
other matches above 97% identity. OTUs were then created by grouping at the genus level. 
Only OTUs with an abundance of at least 1% across all samples were included for further 
analysis, leaving only 10 unique genera. To calculate centered log-ratios for compositional 
analysis (223), zero-value OTU counts were replaced with an estimate value, then 
subjected to CLR calculation. Resulting CLRs were graphed in stacked barplots using R 
(r-project.org). 
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2.5.8 Absolute quantification RT-qPCR 
Real time (RT)-qPCR was performed on swab gDNA for 16S or 16S-23S rRNA gene of 
A. vaginae, G. vaginalis, L. crispatus, L. gasseri, L. iners, L. jensenii, L. vaginalis, and 
total Lactobacillus, and the mucin-desulfatasing sulfatase mdsC gene from P. bivia, as 
previously described (224, 225). Concentrations of forward and reverse primers in each 
reaction were as follows: 200 nM (LgassF/LgassR, InersFw/InersRev, 
LV16s_23s_F/LV16s_23s_R3, M. curtisiiF/R, PBsulF/PBsulR), 150 nM (LBF/LBR), 100 
nM (LcrisF/LcrisR), 300 nM (LjensF/LjensR), 700 nM (AV-F/AV-R), 1250 nM (F-GV1) 
and 625 nM (R-GV3). Reactions were performed in triplicate with 5 µL of 100-fold diluted 
gDNA, 5 µL of primers at their optimal concentration in ddH2O, and 10 µL Power SYBR® 
Green PCR Master Mix (Life Technologies, Warrington, UK). Amplification was 
mediated by the 7900HT Fast Real-Time PCR System (Thermo), with cycling parameters 
indicated in Table 2.1. To detect primer dimers and other non-target double-stranded DNA, 
cycling was followed by melt curve analysis. No significant contaminant annealing was 
detected (Data not shown). 
Table 2.1: Primer and thermal cycling parameters for RT-qPCR 
Target Primer sequence (5’ to 3’) Thermal cycling 
parameters 
 
Total 
Lactobacillus 
LBF: 
ATGGAAGAACACCAGTGGCG 
LBR: 
CAGCACTGAGAGGCGGAAAC 
15 min 
95 °C 
37x 15s 95 °C, 
45s 50 °C, 
45s 72 °C 
L. iners InersFw: GTCTGCCTTGAAGATCGG 
InersRev: 
ACAGTTGATAGGCATCATC 
15 min 
95 °C 
35x 15s 95 °C, 
55s 60 °C, 
60s 65 °C 
L. crispatus LcrisF: 
AGCGAGCGGAACTAACAGATTTA
C 
LcrisR: 
AGCTGATCATGCGATCTGCTT 
15 min 
95 °C 
40x 15s 95 °C, 
60s 60 °C, 
20s 72 °C 
L. gasseri LgassF: 
AGCGAGCTTGCCTAGATGAATTTG 
LgassR: 
TCTTTTAAACTCTAGACATGCGTC 
15 min 
95 °C 
40x 15s 95 °C, 
60s 57 °C, 
60s 65 °C 
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L. jensenii LjensF: 
AAGTCGAGCGAGCTTGCCTATAG
A 
LjensR: 
CTTCTTTCATGCGAAAGTAGC 
15 min 
95 °C 
40x 15s 95 °C, 
55s 60 °C, 
60s 72 °C 
L. vaginalis LV16s_23s_F: 
GCCTAACCATTTGGAGGG 
LV16s_23s_R3: 
CGATGTGTAGGTTTCCG 
15 min 
95 °C 
37x 15s 95 °C, 
30s 56 °C, 
30s 72 °C 
A. vaginae AV-F: CCCTATCCGCTCCTGATACC 
AV-R: 
CCAAATATCTGCGCATTTCA 
10 min 
95 °C 
40x 15s 95 °C, 
20s 64 °C, 
25s 72 °C 
G. vaginalis F-GV1: 
TTACTGGTGTATCACTGTAAGG 
R-GV3: 
CCGTCACAGGCTGAACAGT 
10 min 
95 °C 
40x 45s 95 °C, 
45s 55 °C, 
45s 72 °C 
M. curtisii F: 
GCGATGGTTCCAGAGATGGGCCA
GCCTT 
R: CACGAGTCCCCGGCCGAA 
2 min 
95°C 
40x 60s 95°C, 
60s 65°C, 
60s 72°C 
P. bivia PBsulF: 
ACGTTTGGGCAAAGCTCCTTGTCT 
PBsulR: 
GCGTGTACGCCAGTTGCAAGA 
1 min 
95 °C 
40x 15s 94 °C, 
40s 58 °C, 
30s 72 °C 
Bacterial quantities (in cells/mL) were then calculated by comparison to a standard curve 
of genomic DNA from pure culture of the reference species (see bacterial strains above). 
Isolated DNA from L. iners was used as a standard for total Lactobacillus, due to the 
common abundance of this organism in the vaginal microbiota (180). Total copies of the 
gene of interest in standards were calculated using total DNA content from measurements 
by the NanoDrop® ND-1000 Spectrophotometer (NanoDrop Technologies, Inc., 
Wilmington, DE) and known gene copies per genome by searching the organism in the 
NCBI Genome database. Non-detects were treated as containing no DNA and averaged 
with concentrations of other replicates to reduce positive bias (226). 
2.5.9 Metabolomics on vaginal swab supernatants 
2.5.9.1 Targeted gas chromatography-mass spectrometry 
To precipitate proteins, 100 µL of supernatant from swabs grown in prebiotics (above) 
were diluted with 200 µL of 1:1 methanol:H2O, vortexed for 10 seconds, then centrifuged 
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for 10 min at 10 000 × g. Half (150 µL) of the supernatant was collected into a vial, along 
with 2 µL of 1 mg/mL ribitol internal standard, where they were dried in a speedvac without 
heat. Samples were derivatized with 50 µL of 2% methoxyamine-HCl in pyridine (MOX) 
at 50°C for 90 min, followed by 50 µL of N- Methyl-N- (trimethylsilyl)-trifluoroacetamide 
(MSTFA) at 50°C for 30 min. To prepare for injection, samples were transferred into 
micro-inserts. 
One μL of sample was injected into an Agilent (Santa Clara, CA) 7890A GC, 5975 inert 
MSD with triple axis detector. Samples were injected using pulsed splitless mode using a 
30 m DB5-MS column with 10 m Duraguard, diameter 0.35mm, thickness 0.25 μm (J&W 
Scientific, Folsom, CA). Helium was used as the carrier gas at a constant flow rate of 1 
mL/min. Oven temperature was held at 70°C for 5 min then increased at a rate of 5°C/min 
to 300°C and held for 10 min. Solvent delay was set to 7 min, and total run time was 61 
min. Masses between 25 m/z and 600 m/z were selected by the detector. Samples were run 
in random order, and one specific sample was included in every batch as a quality control 
for machine consistency. 
Chromatogram files were deconvoluted and converted to ELU format using AMDIS Mass 
Spectrometry software (227) with the sensitivity set to low, resolution to medium, and 
support threshold to high. Chromatograms were aligned using Spectconnect 
(http://spectconnect.mit.edu) (228) with the support threshold set to low. The integrated 
signal (IS) matrix output was used for all further analysis. Zeros were replaced with two 
thirds the minimum detected value on a per metabolite basis followed by a log base 2 
transformation. All further analyses were performed using these log-transformed values. 
Identities of known metabolites of interest were confirmed by comparison to standards. 
2.5.9.2 Targeted liquid chromatography-mass spectrometry 
Due to poor separation of lactate peaks using GC-MS, liquid chromatography was used to 
quantify lactate. Samples were vortexed for 15 sec, then transferred to micro-inserts and 
directly injected into an Agilent 1290 Infinity HPLC coupled to a Q-Exactive Orbitrap 
mass spectrometer (Thermo-Fisher) with a HESI (heated electrospray ionization) source. 
For HPLC, 2 μL of each sample was injected into a ZORBAX Eclipse plus C18 2.1 × 50 
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mm × 1.6 micron column. Mobile phase (A) consisted of 0.1% formic acid in water and 
mobile phase (B) consisted of 0.1% formic acid in acetonitrile. The initial composition of 
0% (B) was held constant for 30 sec and increased to 100% over 3.0 min. Mobile phase B 
was then held at 100% for 1.5 min and returned to 0% over 30 sec for a total run time of 6 
min.  
Full MS scanning between the ranges of m/z 50-750 was performed on all samples in 
negative mode at 140 000 resolution. The HESI source was operated under the following 
conditions: nitrogen flow of 25 and 15 arbitrary units for the sheath and auxiliary gas 
respectively, probe temperature and capillary temperature of 425°C and 260°C respectively 
and spray voltage of 3.9 kV. The automatic gain control (AGC) target and maximum 
injection time were 3 × 106 and 500 ms respectively. For molecular characterization, every 
tenth sample was also analyzed with a data dependent MS/MS method where a 35 000 
resolution full MS scan identified the top 12 signals above a threshold of 8.3 × 104, which 
were subsequently selected at a 1.2 m/z isolation window for MS/MS. Normalized collision 
energy for MS/MS was 28, resolution 17 500, AGC target 105 and maximum injection time 
was 60 ms. Blanks of pure methanol and water were run between every sample to limit 
carryover, and a single sample was run multiple times with every batch to account for 
sample variation. After data acquisition, Thermo .RAW files were converted to .MZML 
format and centroided using ProteoWizard (229). Files were then imported into R using 
the XCMS package (230) for chromatogram alignment and deconvolution. Features were 
detected with the “xcmsSet” function using the “centWave” method and a 1 ppm tolerance. 
Prefilter was set to 3-5000, noise 103, and signal to noise threshold was set to 5 in negative 
mode. Retention time correction was conducted using the “obiwarp” method, grouping 
included features present in at least 25% of samples, allowable retention time deviation 
was 5 seconds, and m/z width set to 0.015. Areas of features below the signal to noise 
threshold in the data were integrated using the “fillPeaks” function with default settings. 
Any remaining zeros in the data were then replaced with two-thirds the minimum value on 
a per mass basis before log base 2 transformation. The log-transformed mass list was then 
exported as a single .txt file and used for all further analyses. For principle component 
analysis, data were pareto scaled using the “MetabolAnalyze” package in R. Principle 
components were then plotted using the “pca” function from the “FactoMineR” package 
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in R, and no grouping was observed (Data not shown). Identities of metabolites were 
determined by authentic standards based on accurate mass, retention time and MS/MS 
spectra. 
2.5.10 Statistical analysis 
Growth curves and pH bar plots were graphed and statistically analyzed using GraphPad 
Prism 6 (La Jolla, CA). Significantly enhanced growth compared to no prebiotic media 
control was identified using repeated measures two-way ANOVA with Dunnett’s multiple 
comparisons test. Kruskall-Wallis’ with Dunn’s multiple comparisons test was used to 
identify differences in pH compared to no prebiotic media control. Figure 2.3 was prepared 
using R. 
  
61 
 
Chapter 3  
 
Effects of in vitro lactulose administration on vaginal epithelial 
viability and Lactobacillus crispatus antimicrobial properties 
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 Abstract 
Resident microbes and the epithelial lining form the first line of defense against microbial 
pathogens in the vagina. In healthy women, lactobacilli are the main colonizers and secrete 
abundant antimicrobial lactic acid to contribute to acidic pH. We previously showed that 
the prebiotic lactulose ubiquitously stimulated vaginal Lactobacillus crispatus strains to 
grow and produce acidic metabolites, but no research to date has examined how selectively 
utilized compounds affect bacterial-bacterial and bacterial-host interactions in the vagina. 
Herein, we show that acids produced by L. crispatus fermentation of lactulose are toxic to 
common dysbiosis-associated organisms Gardnerella vaginalis, Atopobium vaginae, and 
Prevotella bivia, and that this activity could be abrogated with supernatant neutralization. 
Although lactulose treatment was detrimental at high doses to epithelial activity, it did not 
disrupt L. crispatus attachment to these host cells. With growing interest in prebiotic 
utilization at sites distant to the gut, properties additional to fermentation should be 
considered. 
 Introduction 
Vaginal health is dependent on the barrier properties imparted by the vaginal epithelium 
and the resident microbes lining it (231–233), as well as their various secretions (49). This 
barrier forms the primary defense system against not only dysbiosis (53, 179), but also 
invading pathogens such as Candida albicans (190, 234–236), Trichomonas vaginalis (99, 
237), Chlamydia trachomatis (22, 23), and HIV-1 (44, 62, 97). The tightly enmeshed 
stratified squamous epithelium of the vagina limits the passage of harmful bacteria and 
protects from shear forces, while also providing a surface for selective bacteria to adhere 
(238). In healthy women, this microbial population is dominated by Lactobacillus species, 
with few other organisms present (180, 193). Along with their metabolites, this community 
of bacteria is termed the vaginal microbiome, and forms a protective layer upon the vaginal 
epithelium. Acidic vaginal pH, formed by Lactobacillus-derived lactic acid, is particularly 
essential for maintaining microbial symbiosis (56, 60). However, additional secretions 
from vaginal lactobacilli are thought to impart defensive properties to the environment, 
including surfactants that inhibit attachment and colonization of pathogens (72), and 
bacteriocins that selectively kill similar bacteria (239). 
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Not all lactobacilli are created equal. Depending on the predominant Lactobacillus species, 
women vary in vaginal pH, stability during temporal fluctuations of the microbiome, and 
susceptibility to infection (39). Of the common species, L. crispatus provides the most 
beneficial properties to the vaginal niche. Compared to other lactobacilli, individuals 
colonized by L. crispatus have more acidic vaginal pH, microbiome stability throughout 
the menstrual cycle, and are less likely to be co-colonized by BV-causing organisms (39, 
193). Because of this, research has been conducted to elucidate properties unique to L. 
crispatus that make it well-adapted to support vaginal health and dominate this niche. The 
ability of L. crispatus strains to readily adhere to the vaginal epithelium, through the 
expression of fibronectin-binding proteins, and produce exopolysaccharides (EPSs) 
necessary for biofilm formation (66, 79) represent adaptation traits in this bacterium. In 
addition, L. crispatus secretes more acidic by-products than other vaginal lactobacilli and 
contain genes for bacteriocin production (65, 66). These beneficial properties make L. 
crispatus an ideal target for stimulation by prebiotic interventions. 
Prebiotics, which are compounds that selectively stimulate beneficial bacteria to cause a 
health benefit to the host (132), are a promising therapeutic to this end. Although this newly 
recognized definition of prebiotics may encompass compounds with several benefits to the 
host and host microbiome, little research has evaluated their effects outside of their ability 
to selectively stimulate commensal bacteria. Our previous work demonstrated that 
lactulose ubiquitously stimulated vaginal isolates of L. crispatus obtained from women 
both with or without BV, resulting in production of acidic by-products, namely lactic acid 
(Collins et al., 2018). However, other benefits of prebiotic therapeutics may include 
improved antagonism of L. crispatus against dysbiotic organisms, stronger adhesion of 
commensal L. crispatus to vaginal epithelium, and enhanced viability of the epithelial layer 
itself. These have not, so far, been explored. 
Recently, an increased interest in developing novel antibiotics derived from human 
commensals has led to the discovery of several new potential antimicrobials, including 
peptides with a narrow range of activity termed bacteriocins. Although these compounds 
vary greatly in their structure, they tend to target similar microbes to the producer to 
provide an advantage in their niche. Considering the propensity of L. crispatus to retain 
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dominance in the vaginal microbiota, bacteriocins may play a role in preventing the 
colonization of BV organisms. The core genome of L. crispatus contains two conserved 
putative bacteriocins with genetic similarity to enterolysin A and helveticin J (66), though 
their actual expression and spectrum of activity remains unknown. Other bacteriocins 
derived from vaginal Lactobacillus species have been characterized for their ability to 
target urogenital pathogens such as Escherichia coli and Enterococcus faecalis (65), 
providing a basis to explore this concept for the prevention of BV. 
Lactulose fermentation may also affect the adherence potential of vaginal lactobacilli. 
Sugar availability is known to alter the expression of adherence-related proteins in bacteria, 
and is a direct substrate for the synthesis of EPS (240). More indirectly, at a low pH, 
fermentation in lactobacilli can change surface properties to promote adhesion to intestinal 
epithelium (187). Although this has not been tested in the vaginal niche, lactulose will 
undoubtedly influence protein expression and/or secretion in the lactobacilli that ferment 
it. Direct application of oligosaccharides can also disrupt carbohydrate-dependent adhesion 
of bacteria by blocking adherence protein interactions to host receptors (241). Therefore, 
it is important to evaluate the effects lactulose might have on attachment of commensal L. 
crispatus to vaginal epithelium to determine whether it may have detrimental or beneficial 
properties in this regard.  
Although human cells do not possess the metabolic capacity to degrade lactulose, research 
has yet to evaluate its effects when applied to human tissues. One study observed that 
lactulose has a protective effect in colonic HT-29 cells against bile acids and fecal water 
(242), though no mechanism was established. With the ultimate goal of human application, 
lactulose must be thoroughly assessed on its interacting host tissue. Our aim was to measure 
vaginal cell viability upon lactulose treatment. These experiments were designed to provide 
insight into lactulose’s effects on the viability of vaginal epithelium and L. crispatus, and 
uncover how it regulates interactions with organisms involved in BV.  
 Results 
To determine how by-products from L. crispatus fermentation of lactulose affect the 
viability of BV organisms, G. vaginalis, A. vaginae, and P. bivia were inoculated in 
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lactulose- or control-treated L. crispatus supernatants. Compared to control-treated 
supernatants, lactulose-treated L. crispatus supernatants had a significant killing effect to 
G. vaginalis (p<0.0001) and P. bivia (p<0.0001), and a similar, but not significant trend 
for A. vaginae (Figure 3.1). However, neutralizing these supernatants to pH 8.0 restored 
the viability of inoculated BV organisms to levels comparable to control (Figure 3.1).  
Using the vaginal epithelial cell line VK2/E6E7, L. crispatus adherence upon lactulose 
treatment was evaluated. Despite glucose-treated L. crispatus having greater attachment to 
vaginal cells, lactulose growth had no effect on attachment (Figure 3.2). Further to this, 
lactulose was directly tested for effects on VK2/E6E7 viability. In a dose-dependent 
manner, lactulose lowered the viability of vaginal epithelial cells (Figure 3.3). 
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Figure 3.1: Lactulose-treated L. crispatus has pH-dependent antagonism against BV 
organisms 
Time-kill assay of BV organisms anaerobically inoculated in spent supernatants from L. 
crispatus in 0.5% lactulose-supplemented or control dextrose-free MRS. Supernatants 
were neutralized using HCl and NaOH and sterilized using 0.2 µm filters. Dotted line 
represents the limit of detection for viable bacteria. Significant differences in viability 
between treatments at 48 hours determined using RM two-way ANOVA with Sidak’s 
multiple comparisons test (****p<0.0001). 
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Figure 3.2: Lactulose does not affect L. crispatus attachment to vaginal epithelium 
Approximately 106 L. crispatus cells were incubated for 1 hour on fully differentiated 
VK2/E6E7 vaginal cells. Adherence expressed as a percentage of L. crispatus bacteria 
seeded onto VK2/E6E7 cells. Statistical significance was determined according to one-way 
ANOVA and Dunnett’s multiple comparison’s test (*p<0.05). 
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Figure 3.3. Lactulose is inhibitory to VK2/E6E7 cell viability in a dose-dependent 
manner 
Viability of the vaginal epithelium (VK2/E6E7) cell line determined using the Vybrant® 
MTT cell proliferation assay kit (ATCC). Various concentrations (% w/v) of lactulose were 
added to KSFM and incubated for one hour before readout. Significant differences to 
control determined using one-way ANOVA with Dunnett’s multiple comparisons test 
(****p<0.0001). 
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 Discussion 
This short report has demonstrated the potential mechanisms of action that lactulose has 
on the barrier properties of the vaginal ecosystem. Importantly, fermentation of lactulose 
stimulates L. crispatus to produce abundant acidic products that are detrimental to the 
viability of BV organisms and could fundamentally alter the selective environment present. 
However, it does not alter the ability of this bacterium to attach to vaginal epithelium, and 
may have a directly detrimental effect on tissue proliferation. 
Direct antagonism of lactobacilli against dysbiotic organisms is a well-studied, essential 
feature of lactobacilli for maintaining vaginal homeostasis. We report here a stimulation of 
this activity in the strongly health correlated L. crispatus against key microbes involved in 
BV, which is abolished at neutral pH. Although it could be posited that this pH-dependent 
secretion from L. crispatus is a protein whose action is inactivated at neutral pH, several 
features suggest otherwise. Firstly, L. crispatus-dominated vaginal microbiotas have a 
significantly lower pH than other predominant lactobacilli, suggesting that it has a greater 
capacity to produce acidic fermentation metabolites. Since fermentation of lactulose by L. 
crispatus dramatically lowers the pH (Collins et al., 2018) and BV organisms are known 
to be susceptible to acidity, it follows that this is responsible for their death in L. crispatus 
supernatants. 
Though no studies have isolated or characterized the predicted bacteriocins present in the 
L. crispatus genome, this species possesses ones that have high nucleotide congruence with 
enterolysin A, helveticin J (66), and gassericin A (65). These bacteriocins were initially 
identified in Enterococcus faecalis, Lactobacillus helveticus, and L. gasseri, respectively, 
and have bactericidal activity against sensitive indicators within a broad pH range, 
including neutrality, and under anaerobic conditions (65, 243–245). Since no killing effects 
were observed in the present work at neutral pH, this suggests that bacteriocins were not 
responsible for antagonism against the BV-associated bacteria. Furthermore, bacteriocins 
are antimicrobials that typically target bacteria similar to the producer species; they occupy 
the same nutritional and physical niche. As the observed activity affects diverse species 
(G. vaginalis, A. vaginae, and P. bivia), which are quite distinct in their metabolic capacity, 
lineage, and physical structure from L. crispatus, it is unlikely that bacteriocins are 
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responsible. Lastly, bacteriocins are not abundantly produced unless bacteria are cultured 
on a solid surface such as agar, while broth medium was utilized here. 
Considering the abundant factors involved in bacterial adhesion to host tissue, it is not 
necessarily surprising that lactulose had no effect on this property of L. crispatus. Despite 
some variation between strains, L. crispatus adhesion in the urogenital tract is 
predominantly receptor-mediated through adhesins and therefore not due to non-specific 
interactions such as hydrophobicity (45, 246). This binding exists only at low pH, which 
could not be obtained in the present assay while still maintaining epithelial cell viability, 
potentially explaining these results. 
Currently, the adhesins responsible for L. crispatus ATCC 33820 attachment are unknown. 
In other lactobacilli, adhesins can bind to either vaginal epithelium receptors or to mucosal 
secretions. An example of the former in L. crispatus is the Lactobacillus epithelium adhesin 
(LEA) protein, which mediates binding to outermost epithelial cells (76), but this protein 
is not present in ATCC 33820. Though not yet established in L. crispatus, mucus-binding 
proteins (247) are found in other vaginal lactobacilli. Although the selection of VK2 
(E6/E7) cells was based partially on their ability to produce mucin 5B (234), many other 
mucins found in cervical secretions could also be targets for L. crispatus adherence. Thus, 
an extension of this work should utilize primary cell lines and ultimately human subjects 
to evaluate adhesion. 
Importantly, there was no negative impact of lactulose on Lactobacillus adhesion, as some 
prebiotics and other oligosaccharides have been observed to do this (248). Because most 
interactions between bacteria and the vaginal epithelium or mucous rely on attachment 
through glycoproteins or other carbohydrate-based moieties, free saccharides are able to 
bind these sites and therefore shield them from interaction, sometimes even actively co-
aggregating bacteria (75, 249). In this case, lactulose averts these effects, possibly due to 
its dissimilar structure to mannose and other sugar components of adherence proteins, but 
also because it is actively degraded by L. crispatus. 
The unexpected dose-dependent detriment of lactulose to VK2 cell viability emphasizes 
the need to carefully select active concentrations in developing treatments in humans, 
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particularly since the mechanism of action is currently unknown. Lactulose derivatives 
have also been shown to induce apoptosis in melanoma cells through inhibition of galectin 
signaling, but these compounds are significantly modified and contain additional lactose 
residues and amines (250). Nonetheless, certain pitfalls of cell culture cast doubt on the in 
vivo translation of this result. Although VK2 cells produce mucin 5A, the vaginal wall is 
typically coated with secretions from not only vaginal epithelial cells, but also originating 
from the Bartholin’s gland and the cervix (251). This protective coat would limit the 
sugar’s direct interaction with host tissue. In addition, VK2 cells lack the ultrastructure of 
the vaginal wall, a stratified squamous tissue, where the outermost layer consists of 
pyknotic cells with no metabolic activity, preparing to be shed (238). Thus, lactulose would 
not contact active epithelium unless damage were to occur. Given these limitations and the 
effectiveness of 0.5% (w/v) lactulose in stimulating lactobacilli, this low dose should be 
considered for vaginal administration. 
The beneficial properties of lactulose on L. crispatus are shown here to be specifically 
mediated by increased lactic acid production and acidic pH, while bacterial adherence is 
not affected. This is not necessarily a limitation, as the sheer quantity of lactic acid 
profoundly improves L. crispatus antagonism against BV organisms both in culture and in 
vivo, and represents a significant aspect of vaginal health. Given the current limitations of 
cell culture, lactulose should still be considered for use in retaining a lactobacilli-dominated 
vaginal microbiota. 
 Materials and Methods  
3.5.1 Time-kill assay 
To obtain spent supernatants, L. crispatus ATCC 33820 was grown for 24 hours in 0.5% 
(w/v) lactulose-supplemented or control dextrose-free MRS, then centrifuged at 4500 × g 
for 5 min. In order to measure the effect of pH on antagonism, half of the supernatants from 
each condition were neutralized to pH 8.0 ± 0.1 with HCl and NaOH. Supernatants were 
then sterilized using 0.2 µm filters. BV organisms G. vaginalis ATCC 14018, A. vaginae 
ATCC BAA-55, P. bivia ATCC 29303, and M. curtisii ATCC 35241 were inoculated into 
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sterile L. crispatus supernatants at approximately 106 CFU/mL and growth was monitored 
using spot plating method on Columbia Blood Agar (CBA) every 3 hours. 
3.5.2 Effects of lactulose on L. crispatus adherence to vaginal epithelium and 
epithelial viability 
The vaginal epithelium cell line VK2/E6E7 (ATCC CRL-2616) was cultured in 
keratinocyte serum-free media supplemented with 50 µg/mL of bovine pituitary extract, 
0.1 ng/mL of epidermal growth factor and 0.4 mM CaCl2 (Life Technologies, Gibco) at 
37°C and 5% CO2. 
For the adherence assay, VK2/E6E7 cells were inoculated into a 24-well plate to a density 
of 105 viable cells/well and allowed to fully differentiate. L. crispatus was grown in 1% 
(w/v) lactulose-supplemented, 2% (w/v) dextrose, or control dextrose-free MRS for 18 
hours. Approximately 107 CFU/mL L. crispatus from each pre-treatment were then seeded 
onto VK2/E6E7 cells for 1 hour. Cells were briefly rinsed with PBS to remove non-
adherent bacteria. Remaining adherent bacteria were dislodged by treating cells with 0.05% 
trypsin for 10 min, then plated on MRS to determine viable counts. 
In order to measure the viability of VK2/E6E7 in lactulose, KSFM solutions with 
increasing concentrations of lactulose (0.5%, 1%, and 5% w/v) were prepared. Once 
VK2/E6E7 cells reached approximately 80% confluence and were therefore still actively 
proliferating, cell media was replaced with lactulose-treated or control media. Cells were 
incubated for 1 hour, then viability was determined using the Vybrant® MTT cell 
proliferation assay kit (ATCC), according to the manufacturer’s instructions. 
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Chapter 4  
 
Influence of glycogen metabolism on the vaginal microbiota 
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 Abstract 
Selective stimulation of bacteria by abundant glycogen in the vaginal ecosystem 
undoubtedly helps to shape the composition of the resident microbiota. Although it was 
previously thought that lactobacilli were the main beneficiaries of this carbon source, we 
observed here that L. crispatus, L. gasseri, and L. jensenii were not stimulated by glycogen, 
while L. iners, and bacterial vaginosis (BV)-associated G. vaginalis, P. bivia, M. curtisii, 
and A. vaginae were. To better understand the impact of this fermentation on bacterial 
interactions, supernatants were collected, replenished with glycogen, and L. iners or BV-
associated organisms were re-inoculated. Growth in glycogen appeared self-limiting, as L. 
iners and G. vaginalis grown in their own supernatants were rapidly killed. Furthermore, 
metabolites from L. iners growth in glycogen were antagonistic toward these BV-
associated organisms. Supernatant neutralization revealed that acidic pH was responsible 
for killing P. bivia and M. curtisii. In contrast, antagonism of G. vaginalis by L. iners could 
not be explained by pH, depletion of nutrients required for glycogen metabolism, or 
secretion of amylase-inhibiting lactic acid. Given the current lack of knowledge regarding 
glycogen utilization by vaginal microorganisms, further investigations into this interaction 
between host and bacteria should be considered before interventions using glycogen are 
introduced.  
 Introduction 
Glycogen, a polysaccharide consisting of glucose monomers linked linearly by α-1,4-
glycosidic bonds with branching α-1,6-glycosidic bonds, is the major carbon source 
available in the female genital tract (238). It is predominantly produced by the stratified 
epithelium lining the vaginal canal, then freed into surrounding cervicovaginal fluid when 
the outermost cells are sloughed off and broken apart by bacterial cytolysins (252, 253). 
Typical levels of free vaginal glycogen in cervicovaginal fluid are highly variable in 
healthy women, ranging anywhere from 0.1–32 μg/μL (188). This variation is generally 
attributed to differences in circulating estrogen, which triggers glycogen production in 
vaginal epithelial cells (34, 188). Since estrogen concentrations fluctuate throughout the 
menstrual cycle and are depleted following menopause, so too do vaginal glycogen levels 
vary (37, 38). 
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Like all abundant carbon sources in any given ecosystem, glycogen plays an essential role 
in selecting for and shaping the microbes that can survive in this niche, as those that express 
the genes necessary to utilize glycogen will have a metabolic advantage. Since glycogen 
commonly acts as a glucose storage vehicle in prokaryotes and eukaryotes alike, many 
bacteria already possess the machinery necessary to degrade intracellular glycogen (254). 
This typically includes a glycogen phosphorylase, a α-1,4-glycosidase that cleaves off 
smaller sugars from ends of glycogen’s linear chains (255) and a debranching enzyme that 
targets the α-1,6-glucose branching points (256). However, glycogen’s complex, highly 
branched structure prevents its transport across cell membranes; thus, these enzymes must 
be secreted outside the cell. Once the extracellular glycogen is broken into its glucose and 
maltose components, carbohydrate transporters such as phosphotransferases are required 
to actively import them into the cell (257, 258). Most of these enzymes have been 
characterized in Escherichia coli strains, and there has been surprisingly little research to 
date on their expression in common vaginal bacteria, despite the prevalence of this carbon 
source in the vagina. 
Because of this gap in knowledge, there remains significant controversy over glycogen’s 
net impact on vaginal microbiota homeostasis. Initially, glycogen was thought to 
supplement vaginal lactobacilli because high glycogen levels were associated with a 
Lactobacillus-dominant microbiota and acidic vaginal pH (34, 188, 189). In particular, 
glycogen concentrations are elevated in microbiota colonized primarily by L. crispatus and 
L. jensenii, compared to L. iners (189). Nevertheless, despite few rare species of 
lactobacilli (L. acidophilus, L. leichmannii, and L. salivarius) having the ability to utilize 
glycogen (259), commonly dominant strains of L. crispatus, L. jensenii, and L. gasseri, as 
well as L. plantarum, have been observed to not utilize it at all (190). This paradigm was 
seemingly resolved with the discovery that human α-amylases are also released by 
epithelial cells into vaginal fluid, where they metabolize glycogen into glucose and maltose 
(191). Thus, the host was believed to extracellularly degrade glycogen into counterparts 
fermentable by lactobacilli, where they increased in composition and released acidic lactic 
acid as a by-product. This non-specific mechanism is problematic though, because these 
simple sugars are metabolized almost ubiquitously by bacteria. Furthermore, these studies 
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did not include the most abundant Lactobacillus colonizer, L. iners, which has not yet been 
evaluated for glycogen fermentation ability. 
In order to fully comprehend its impact on the vaginal microbiota, it is important to 
consider glycogen metabolism by microbes that are not beneficial to the host. A diversity 
of such organisms emerge in a common condition known as bacterial vaginosis (BV), 
where the commensal Lactobacillus population and acidic pH are depleted (82). 
Conversely, levels of strictly anaerobic bacteria increase, sometimes causing unpleasant 
odor and discharge (58, 260), as well as increased risk for infections (22). Upon comparison 
of the bacterial transcriptome during vaginal health and BV, Macklaim et al. (83) observed 
that genes responsible for glycogen metabolism were upregulated during BV and were 
mapped to several BV-associated organisms. The genome of G. vaginalis, a predominant 
organism involved in BV pathogenesis, contains conserved genes for glycogen catabolism 
(261). It is reasonable to postulate then, that glycogen may stimulate the growth of 
unwanted BV organisms rather than lactobacilli. We therefore aimed to measure the 
glycogen fermenting capacity of both common vaginal lactobacilli and BV-associated 
bacteria, and elucidate how this influences the interaction between these members of the 
vaginal microbiota. 
 Results 
4.3.1 Glycogen fermentation by common vaginal lactobacilli and BV-
associated organisms 
Upon inoculation of preferred media with 0.5% glycogen, growth of L. iners was 
stimulated, while all other lactobacilli were not affected (Figure 4.1A and B). This directly 
coincided with significant media acidification in L. iners supplemented with glycogen 
compared to control (p<0.0001, Figure 4.2). As glycogen metabolism by L. iners has not 
yet been evaluated, we searched its transcriptome for genes potentially responsible for this 
phenotype. L. iners was found to increase its expression of pullulanase, a starch degrading 
enzyme, during BV onset (Macklaim et al., unpublished). Common BV organisms G. 
vaginalis and A. vaginae increased in viability with glycogen as the sole carbon source, at 
early time points for the former (p<0.0001) and at 48 hours for the latter organism (p<0.05) 
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Figure 4.1: Growth of common vaginal lactobacilli in 0.5% glycogen 
Growth of predominant vaginal Lactobacillus species in dextrose-free NYC III (L. iners) 
or MRS (all others), with or without supplementation with 0.5% (w/v) glycogen. (A) 
Viability (in CFU/mL) was tracked using spot plating, with significance determined at each 
time point using mixed ANOVA with Sidak’s multiple comparisons test (***p<0.001, 
****p<0.0001). (B) Total bacteria (OD600) after reaching plateau phase of growth, with 
significance determined using Student’s t-test (****p<00001). 
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Figure 4.2: Media pH following growth of common vaginal lactobacilli in 0.5% 
glycogen 
Media acidity measured using pH test strips following plateau phase of Lactobacillus 
growth in dextrose-free NYC III (L. iners) or MRS (all others), with or without 
supplementation with 0.5% (w/v) glycogen. Significance determined using Student’s t-test 
(****p<0.0001). 
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(Figure 4.3A). This resulted in greater overall turbidity for both bacteria (p<0.0001, 
Figure 4.3B), as well as significant drops in media pH following growth (p<0.01 and 
p<0.05; Figure 4.4). Although P. bivia and A. vaginae had no increase in viable counts 
with glycogen administration at the selected time points, both experienced an overall 
increase in bacterial turbidity (p<0.0001 and p<0.05, respectively; Figure 4.3A and B), as 
well as lowered media pH (p<0.01 and p<0.05, respectively; Figure 4.4). 
4.3.2 Bidirectional antagonism of BV-associated organisms and L. iners with 
glycogen stimulation 
Since glycogen-inoculated BV bacteria and L. iners induced media acidity, and BV-
organisms are known to be sensitive to low pH (53), we evaluated their viability in spent 
supernatants of L. iners and BV-organisms’ growth in glycogen. When inoculated in 
glycogen-spent L. iners supernatants, viability of L. iners (p<0.0001), G. vaginalis 
(p<0.0001), M. curtisii (p<0.0001), and P. bivia (p<0.05) fell below the limit of detection, 
significantly lowering them compared to control (Figure 4.5). Restoration of M. curtisii 
and P. bivia was achieved when these supernatants were neutralized to pH 7.0 (Figure 
4.5). In contrast, L. iners and G. vaginalis viability was significantly improved upon 
supernatant neutralization (p<0.0001), but remained lower in abundance than in control L. 
iners supernatants (p<0.05 and p=0.05, respectively; Figure 4.5). 
4.3.3 Lactate does not affect the growth of G. vaginalis or L. iners in 
glycogen 
To determine whether products from G. vaginalis grown in glycogen exerted a similar self-
killing, L. iners-antagonizing effect, G. vaginalis and L. iners were grown in G. vaginalis 
glycogen-spent supernatants. This was also to shed light on whether the previously 
observed killing of G. vaginalis and L. iners by L. iners supernatants was due to the 
depletion of nutrients required for glycogen metabolism. While glycogen-supplemented G. 
vaginalis supernatants significantly antagonized both G. vaginalis (p<0.0001) and L. iners 
(p<0.05) compared to control-grown G. vaginalis supernatants, neutralization completely 
restored their viability to levels comparable to control (p<0.001 and p<0.05, respectively; 
Figure 4.6). 
  
81 
 
 
 
 
 
A 
B 
82 
 
Figure 4.3: Growth of BV-associated bacteria in 0.5% glycogen. 
Growth of BV-associated bacteria in dextrose-free NYC III with or without 
supplementation with 0.5% (w/v) glycogen. (A) Viability (in CFU/mL) was tracked using 
spot plating, with significance determined at each time point using mixed ANOVA with 
Sidak’s multiple comparisons test (*p<0.05, ****p<0.0001). (B) Total bacteria (OD600) 
after reaching plateau phase of growth, with significance determined using Student’s t-test 
(*p<0.05, ****p<00001). 
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Figure 4.4: Media pH following growth of BV-associated bacteria in 0.5% glycogen. 
Media acidity measured using pH test strips following plateau phase of BV-associated 
organism growth in dextrose-free NYC III with or without supplementation with 0.5% 
(w/v) glycogen. Significance determined using Student’s t-test (*p<0.05, **p<0.01). 
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Figure 4.5: Viability of BV organisms in spent glycogen-supplemented L. iners 
supernatants 
L. iners supernatants from growth in dextrose-free NYC III broth with or without 0.5% 
(w/v) glycogen were collected. Subsets of glycogen-grown supernatants were neutralized 
to pH 7 using HCl and NaOH, then all were sterilized with 0.2 µm filters. Supernatants 
were replenished with 0.5% glycogen, then approximately 106 viable bacteria were 
inoculated in supernatants and grown anaerobically for 48 hours. Viability was tracked 
using spot plating at designated time points. Dotted line indicates the limit of detection and 
values falling below were replaced with 2/3 the limit of detection. Significance was 
evaluated on log-transformed values using mixed ANOVA with Sidak’s multiple 
comparisons test (*p<0.05, **p<0.01, ****p<0.0001). 
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Figure 4.6: Viability of G. vaginalis and L. iners in spent glycogen-supplemented G. 
vaginalis supernatants 
G. vaginalis supernatants from growth in dextrose-free NYC III broth with or without 0.5% 
(w/v) glycogen were collected. Subsets of glycogen-grown supernatants were neutralized 
to pH 7 using HCl and NaOH, then all were sterilized with 0.2 µm filters. Supernatants 
were replenished with 0.5% glycogen, then approximately 106 viable G. vaginalis or L. 
iners were inoculated in supernatants and grown anaerobically until control viability 
declined. Viability was tracked using spot plating at designated time points. Dotted line 
indicates the limit of detection and values falling below were replaced with 2/3 the limit of 
detection. Significance was evaluated on log-transformed values using mixed ANOVA 
with Sidak’s multiple comparisons test (*p<0.05, ***p<0.001, ****p<0.0001). 
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Lactic acid is a common by-product of anaerobic fermentation and has been shown to 
potently interfere with alpha-amylases responsible for glycogen metabolism in other 
microorganisms (262). Since L. iners fermentation produces abundant lactic acid, we 
evaluated if the concentrations produced by glycogen metabolism were responsible for 
limiting the proliferation of L. iners and G. vaginalis in glycogen. NYC III broth containing 
glycogen was acidified to pH 4.0 using lactic acid to simulate fermentation products of L. 
iners, then neutralized to the same pH as control media. Interestingly, L. iners and G. 
vaginalis inoculation in this lactate-treated media had no effect on their growth in glycogen 
(Figure 4.7). 
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Figure 4.7: L. iners and G. vaginalis viability in lactate-treated NYC III media. 
Dextrose-free NYC III media with 0.5% (w/v) glycogen was prepared, with or without 
lactate. Lactate treatment was performed by bringing media to pH 4.0 with concentrated 
lactic acid, then neutralizing to pH 7.0 with NaOH. Both conditions were subsequently 
sterilized using 0.2 um filters. Significance between lactate and control was determined on 
log-transformed values using mixed ANOVA with Sidak’s multiple comparisons test. 
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 Discussion 
The present work reveals that, despite previous clarity on the subject, there is still much 
unknown about the role of glycogen in shaping the vaginal microbiome. We report for the 
first time that Lactobacillus iners directly metabolizes glycogen, unlike any other known 
predominant vaginal Lactobacillus spp. Furthermore, the broad glycogen-degrading 
capacity of several common BV-associated microbes is confirmed. We then show that by-
products from this degradation affect the dynamic between glycogen-utilizing vaginal 
organisms, potentially resulting in a self-regulating system. Despite several attempts at 
determining the product(s) responsible for this antagonism, they remain elusive and will 
require further investigation. 
L. iners is the most abundant vaginal Lactobacillus species, being present in instances of 
eubiosis and BV alike (88, 180). Although its cohabitation with dysbiotic organisms has 
led some to conclude that L. iners strains are less beneficial than other lactobacilli, there 
has been substantial debate over whether L. iners is simply better adapted to the vaginal 
niche (46, 47). Proponents of the former cite the observation that an L. iners-dominated 
microbiota tends to fluctuate more to a diverse, BV-like state than other predominant 
lactobacilli (39), tends to have less acidic vaginal pH (193). Furthermore, L. iners strains 
tend not to produce hydrogen peroxide (263, 264), previously thought to play a large role 
in defending against pathogens. While this may be viewed as an inability for L. iners to 
fight off microbes associated with dysbiosis, the latter hypothesis suggests that it may be 
better adapted to survive in and therefore tolerates the invasion of these microbes. This 
flexibility may be a result of its small genome that relies heavily on acquisition of nutrients 
from its environment, or its unique cell-anchoring proteins and carbohydrate utilization 
mechanisms that define its survival in the vagina (47, 48). Regardless, L. iners is 
considered an essential component of the vaginal microbiota in health, especially in women 
from African or Hispanic descent who are commonly dominated by this organism (33, 
193). 
Our finding that L. iners has the unique capacity for glycogen degradation largely supports 
this hypothesis, as glycogen is the most abundant carbohydrate source available in 
cervicovaginal fluid (34, 188). It was previously considered very rare for vaginal 
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lactobacilli to process glycogen (48, 191, 259), though no studies directly examined 
utilization by L. iners. However, previous work demonstrated that an L. iners-dominated 
microbiota has greater α-amylase activity than an L. crispatus-dominated vaginal 
microbiota (43). This capability may reflect adaptation mechanisms of L. iners to 
fluctuations in the vaginal environment. During BV, anaerobic organisms consume the 
ample free vaginal glycogen, leaving little for host mucosal α-amylases to digest into 
glucose and mannose (191), the primary carbon sources readily available for L. crispatus, 
L. jensenii and L. gasseri. While this loss is detrimental to other lactobacilli, L. iners 
increases its expression of the epithelium pore-forming protein inerolysin (83, 265), which 
lyses these cells to release glycogen. Given that L. iners upregulates four α-1,6-
glucosidases (83) and a pullulanase during BV that potentially degrade glycogen, it is likely 
that this provides a mechanism for carbohydrate scavenging during low sugar availability. 
Thus, L. iners is able to effectively compete with BV organisms such as Prevotella spp. 
and Gardnerella vaginalis, which also produce cytolysins and glycogen-degrading 
enzymes (83, 252, 253), and which we have directly shown to metabolize glycogen here. 
Further characterization of these gene products in several L. iners strains and confirmation 
of their glycogen-degrading properties will shed light into which genes are truly 
responsible for this phenotype and whether it is broadly conserved across L. iners strains. 
Due to the abundance of this polysaccharide in the vaginal niche, glycogen metabolism 
undoubtedly shapes interactions between inhabitants of the vaginal microbiome. We found 
that glycogen is broadly utilized by common BV organisms, supporting previous 
observations of their genetic capacity to do so (83). Surprisingly, utilization of glycogen 
by these microbes and L. iners produced acidic metabolites that lowered media pH, despite 
their known sensitivity to acid. This brought to question whether the glycogen metabolism 
process was self-limiting, which was indeed the case for both L. iners and G. vaginalis, 
whose supernatants had a self-killing effect. Therefore, glycogen metabolism might help 
to explain the spontaneous recovery from BV that some women experience (266, 267). 
Fluctuations in the vaginal microbiota occur frequently and from a number of known 
factors, including menstruation (37), sexual activity (112), and presence of external 
bacterial reservoirs (115); however, none of these explain the restoration of Lactobacillus 
dominance. We posit that newly burgeoning BV organisms capitalize on the largely 
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concentrated glycogen available in cervicovaginal fluid, rapidly producing acidic 
metabolites that slow their growth and lead to one of two outcomes: (i) Either the acid-
tolerant lactobacilli that may have survived, including L. iners, are able to re-establish 
themselves, or (ii) BV organism metabolism slows to reach homeostasis in a dysbiotic 
state. Longitudinal studies following glycogen and the microbiota will be needed to further 
validate this conclusion. In addition, there is a need for vaginal models that support co-
colonization of epithelial cells with the diversity of microbes present in the human vagina, 
which would better reveal how introduction of BV organisms or changing glycogen 
concentrations affect microbial balance and host symbiosis. 
Another surprising discovery was that, despite similar degrees of acidity produced, L. iners 
supernatants were more detrimental to the viability of L. iners and G. vaginalis than 
products from G. vaginalis. Similarly to other lactobacilli, L. iners carbohydrate 
fermentation produces mainly lactic acid (268), while G. vaginalis secretes predominantly 
acetic acid and some butyric (19), lactic and succinic acids (260, 269). Different acid 
profiles may have varied effects on bacterial survival, with lactic acid being particularly 
toxic to BV-associated organisms (60). This, however, does not rule out additional 
secretions that may impart the increased killing effect of L. iners. 
We used neutralized L. iners supernatants following glycogen stimulation to gain 
additional insight into the characteristics of antagonistic secretions produced. For P. bivia 
and M. curtisii, neutralization of L. iners supernatants completely restored their viability, 
indicating that acidic pH was responsible for this antagonism. In contrast, the remaining 
differences in L. iners and G. vaginalis survival between control and neutralized L. iners 
supernatants suggests an alternative explanation. The most probable being that the initial 
growth of L. iners with glycogen uses up additional nutrients necessary for glycogen 
metabolism. However, since G. vaginalis should utilize the same nutrients to purport this 
phenotype, and neutralized G. vaginalis supernatants had no effect on viability, this is 
unlikely. An alternative hypothesis is that L. iners-derived lactic acid specifically inhibits 
enzymes responsible for glycogen degradation, preventing L. iners and G. vaginalis from 
utilizing this carbon source. Others have shown that lactic acid is a potent bacterial α-
amylase inhibitor (262), which would inhibit the breakdown of glycogen into maltose and 
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glucose by these organisms. We tested whether the concentration of lactic acid that was 
necessary to acidify the media to the same extent as L. iners fermentation was sufficient to 
inhibit the growth of L. iners and G. vaginalis in glycogen at a neutral pH, but no change 
was observed. Perhaps since protonated lactic acid, present at lower pH, is more 
detrimental to bacterial survival, then neutralization abrogates lactic acid’s effect (53). 
Furthermore, the concentration necessary to inactivate alpha-amylases can be extremely 
high, equating to pH 2.93 (270). Thus, lactic acid does not fully explain the antagonistic 
properties of L. iners following growth with glycogen as the primary carbon source. 
With the currently limited research on glycogen’s role in shaping the vaginal microbiota, 
there is a serious need for controlled experiments. Although human studies have correlated 
free vaginal glycogen with a Lactobacillus-dominated microbiota and low pH (188, 189), 
this remains insufficient to justify exogenous administration of glycogen. Certain products, 
such as the Luvena® vaginal moisturizer, have already been developed under the false 
notion that glycogen selectively stimulates commensal lactobacilli. Furthermore, glycogen 
broadly stimulates BV-associated bacteria, shown here, and the parasite Trichomonas 
vaginalis (271). An improved understanding of glycogen metabolism by vaginal microbes 
will provide insight into temporal dynamics of the vaginal microbiota. The apparent self-
limiting nature of glycogen metabolism by BV organisms may warrant fewer antibiotic 
prescriptions for BV, rather focusing on the reintroduction of lactobacilli, such as in a 
probiotic (130, 131). Lastly, future studies should determine the L. iners metabolite 
responsible for the inhibition of glycogen utilization by BV-associated organisms, as the 
potential applicability of such a compound for modulating the vaginal microbiota could be 
profound. Given the clear importance of glycogen in the vaginal environment, this research 
provides a solid foundation for understanding its impact on resident microbes. 
 Materials and Methods 
4.5.1 Bacteria and growth conditions 
Representative strains of vaginal bacteria were selected for glycogen fermentation capacity 
and obtained from ATCC. Lactobacilli used were Lactobacillus iners AB-1, L. gasseri 
ATCC 33323, L. crispatus ATCC 33820, and L. jensenii ATCC 25258, and BV-associated 
92 
 
organisms were Gardnerella vaginalis ATCC 14018, Atopobium vaginae ATCC BAA-55, 
Mobiluncus curtisii ATCC 35241, and Prevotella bivia ATCC 29303. Lactobacilli, except 
L. iners, were cultured in modified de Mann, Rogosa and Sharpe (MRS) media containing 
no dextrose in anaerobic conditions at 37°C. BV-associated organisms and L. iners were 
grown in dextrose-free New York City (NYC) III medium in an anaerobic chamber (80% 
N2, 10% CO2, and 10% H2) at 37°C.  
4.5.2 Measurement of glycogen fermentation 
Bacterial growth was measured upon addition of 0.5% (w/v) glycogen (type II, from oyster, 
Sigma) using both spot plating and optical density measurements. L. gasseri, L. crispatus, 
and L. jensenii were diluted and plated on MRS agar, while L. iners and BV-associated 
organisms grew on Columbia blood agar (CBA). To determine viable counts, spot plating 
was performed at designated time points until plateau phase was reached. Optical density 
reading at 600 nm was then used to approximate total bacteria following growth. Glycogen 
fermentation was determined to occur by measuring the media pH after reaching plateau 
phase. 
4.5.3 Isolation of and growth in bacterial supernatants 
Supernatants were extracted from L. iners and BV-associated bacteria grown in NYC III 
media with or without 0.5% (w/v) glycogen by centrifuging at 4500 × g for 10 min and 
decanting into fresh tubes. Spent glycogen-inoculated supernatants were then either 
untreated or neutralized to pH 7.0 ± 0.2 using HCl and NaOH. Approximately 106 CFU/mL 
bacteria were seeded into supernatants and spot plating was used to measure viability over 
time. 
To determine the effect of lactate in the media on the ability of L. iners and G. vaginalis to 
proliferate in glycogen, dextrose-free NYC III broth with 0.5% glycogen was brought to 
pH 4.0 ± 0.2 with lactic acid, then both this and control glycogen-supplemented NYC III 
broth were neutralized to pH 7.0 ± 0.5 using HCl and NaOH. L. iners and G. vaginalis 
were then inoculated in both media at a density of approximately 106 CFU/mL. 
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Chapter 5  
 
Multi-mycotoxin biomarker detection in a cohort of Rwandan 
women using LC-MS/MS and association with women’s health 
outcomes 
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 Abstract 
Mycotoxins are a widespread problem for food safety and women’s health due to their 
carcinogenic and teratogenic effects and worldwide prevalence. Despite extensive 
reporting of aflatoxins (AF), fumonisins (F), ochratoxin A (OTA) and zearalenone (ZEN) 
in popular Rwandan foods, the exposure levels of these fungal toxins have not been 
explored. In this chapter, I use a state-of-the-art metabolomics approach to quantify a panel 
of mycotoxins in a cohort of 149 Rwandan women that participated in a study of the BV 
microbiota and metabolome to further understand the intersection of women’s health and 
environmental toxins. Plasma AF-albumin was detected in 81% of women at a mean 
concentration of 2.26 pg/mg albumin, representing long-term exposure to AFB1. Urinary 
biomarkers AFM1, FB1, FB2, OTA and ZEN were detected in 49%, 30%, 15%, 71% and 
51% of individuals in this population, with mean quantity of positives being 170, 59, 64, 
684 and 307 pg/mg creatinine, respectively. AFM1, a urinary biomarker for AFB1 
ingestion, was associated with increased intake of vegetables, potentially relating to the 
common contamination of cassava in Rwanda with Aspergillus spp. In addition, elevated 
levels of the plasma AFB1 biomarker AF-albumin were observed in pregnant women. 
Additional studies are needed to delineate the source of contamination in Rwanda, but 
given the known negative consequences of mycotoxin exposure, systematic improvements 
to food processing and storage are drastically needed to reduce exposure in this high-risk 
population. 
 Introduction 
Mycotoxins are a serious concern for human health, especially in the developing world 
where an estimated 4.5 billion people are chronically exposed (192). These compounds are 
secondary metabolites released into the environment mainly by species of three major 
fungi: Aspergillus, Fusarium, and Penicillium. Various crops predominant in developing 
nations in Africa including maize, millet, cassava, peanuts, and products formed from these 
crops, are commonly contaminated by these organisms. This is in large part due to 
environmental conditions, but also because of weaker regulations on food cultivation and 
storage. Typically, fungi require a warm, humid climate and a nutritional host to proliferate 
and produce toxic compounds, which largely resembles the tropical temperament of 
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African countries (272, 273). Therefore, without proper dehumidification, cold storage, 
antifungal application, and frequent chemical testing, fungal contamination can occur 
during several stages of crop preparation, including plant growth, storage, transportation, 
or at the final location of sale (274). Given the food scarcity in impoverished nations and 
the fact that cooking practices do not reduce these compounds’ stability, contaminated 
foods are often still ingested, causing serious problems to human health (275). 
The main mycotoxins of interest and significance to humans are aflatoxins (AF), 
fumonisins (F), zearalenone (ZEN), and ochratoxin A (OTA).  Aflatoxins B1, B2, G1 and 
G2 are common contaminants of maize and peanuts, mostly produced by Aspergillus flavus 
and A. parasiticus (276) among few other Aspergillus spp. (277). Aflatoxin B1 is 
considered a class I carcinogen and is tightly regulated under Health Canada at a maximum 
level of 15 ppb in food. Metabolism of this compound produces a highly carcinogenic 
epoxide, which intercalates DNA to cause mutations and greatly increases the risk for 
cancer development (278–280, 144). This may be partially responsible for the high rates 
of liver cancer in African countries, especially in Rwanda where it is the leading cancer 
(281, 282). High acute exposure also results in aflatoxicosis, a severe form of hepatitis, that 
can lead to jaundice, and potentially death (283). Frequent aflatoxin outbreaks have 
occurred throughout Africa in recent years, perhaps the most notable occurring in 2004 in 
Kenya, resulting in 317 cases of aflatoxicosis and 125 deaths between January and June 
alone (284). Fumonisins B1 and B2, produced by Fusarium spp., almost ubiquitously 
contaminate maize in Africa (158, 285). Along with liver cancer (162), fumonisin intake 
has been associated with esophageal cancer (161) and neural tube defects in development 
(163). Certain Fusarium spp. also produce ZEN, a compound that structurally and 
functionally imitates estrogen, thereby dysregulating endocrine signalling (173), 
potentially stimulating breast cancer progression (174), and causing fetal abnormalities 
(27). Recent work has also observed that ZEN disrupts the immune system, attenuating the 
production of antibodies and macrophage-derived peroxide (286). Similarly to fumonisins, 
ZEN is found in several types of grains and cereals worldwide, including maize and corn 
(287). In contrast, ochratoxin A is not believed to broadly contaminate foods in Africa, 
though its widespread prevalence in European and American beverages, such as coffee and 
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wine, warrants investigation. OTA can be produced by several Aspergillus spp. and 
Penicillium verrucosum, and is mainly associated with nephropathy in humans (177). 
From a women’s health perspective, mycotoxin ingestion is a serious issue in developing 
nations. Not only do the broad carcinogenic and toxic effects apply, but also pathologies 
specifically related to females. For example, exposure to mycotoxins increases risks of 
developing tumours of the endometrial lining, ovaries, and breasts. In addition, pregnant 
women ingesting mycotoxins are at risk for late-term abortion and fetal abnormalities 
because of their toxic effects in development (288). Furthermore, breastfeeding women can 
pass AFM1, FB1, and OTA to newborns, an occurrence reported in women from African 
countries (289). These risks are specifically targeted to women, who contribute 60-80% of 
the agricultural workforce in African countries and are therefore highly exposed to such 
toxins (183). Therefore, women of reproductive age are important in determining the 
effects of environmental toxins on population health, as it directly affects incoming 
generations. 
Though studies in Africa have reported human contact with mycotoxins, the substantial 
differences in climate and eating habits between individual countries warrants investigation 
into the Rwandan population. Our unique focus on Rwandan women is important and well-
founded, since their common food sources have been shown to be significantly 
contaminated with these compounds. Approximately 5.4%, 0.9%, and 46.8% of Rwandan 
cassava crops are reportedly contaminated with deoxynivalenol, ochratoxin A, and 
zearalenone, respectively (157). This crop is the second most popularly consumed crop in 
Rwanda, only proceeded by maize. Though not directly studied in Rwanda, maize is also 
frequently colonized by toxigenic Fusarium and Aspergillus spp. in other populations. 
ELISA measurements of FB1 and ZEN in banana beers made in Kigali, Rwanda also 
quantified mean concentrations of 32.65 and 1.43 µg/kg, respectively (171). Despite 
prevalent contamination of popular Rwandan staple foods with mycotoxins, human 
exposure levels have been under-reported. Since this better reflects clinically significant 
outcomes, we sought to characterize a broad profile of fungal toxins that may be present in 
Rwandan women of reproductive age. 
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 Results 
5.3.1 Multi-mycotoxin detection in plasma and urine of Rwandan women 
Using liquid chromatography-mass spectrometry, plasma AFB1 and urine aflatoxins, 
fumonisins, OTA, and ZEN were quantified in Rwandan women. The largest proportion 
of samples were contaminated with plasma AFB1 at 81%, followed by OTA at 71%, ZEN 
at 51%, AFG1 at 50%, and AFM1 at 49% (Table 5.1). Of values above the limit of 
quantification, the highest mean concentrations occurred for OTA at 684 pg/mg creatinine, 
ZEN at 307 pg/mg creatinine, and AFM1 at 170 pg/mg creatinine (Table 5.1 and Figure 
5.2). Plasma albumin-conjugated AFB1 was present at a mean level of 2.22 pg/mg albumin, 
with measurements ranging from 0.36 to 9.34 pg/mg albumin (Figure 5.1A). While urinary 
AFM1 is a validated biomarker for short-term exposure to dietary aflatoxin B1 (290), AFB1-
albumin reflects exposure over several weeks (291). Therefore, to observe consistency in 
measurements and whether exposure was changing over time, we analyzed samples for 
AFB1-albumin across a 30-day interval. There was some variation within individuals in 
aflatoxin B1 plasma concentrations, but no overall difference was observed (p>0.05, 
Figure 5.1B). 
Table 5.1: Summary of detected plasma and urinary mycotoxin levels 
Mycotoxin 
<LOD # detectable Total 
n 
Mean of 
positives n % n % 
AFB1-lysine 21 19% 91 81% 112 2.22* 
AFM1 68 51% 66 49% 134 169.91
# 
AFB1 124 89% 15 11% 139 6.24
# 
AFB2 130 94% 9 6% 139 2.25
# 
AFG1 70 50% 69 50% 139 14.06
# 
AFG2 127 91% 12 9% 139 1.51
# 
FB1 135 98% 3 2% 138 59.37
# 
FB2 118 85% 21 15% 139 64.41
# 
OTA 41 29% 98 71% 139 684.39# 
ZEN 61 49% 64 51% 125 306.98# 
LOD = limit of detection; * pg/mg albumin; # pg/mg creatinine 
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Figure 5.1: Concentration of AFB1-albumin adduct in plasma of Rwandan women 
Plasma aflatoxin B1 in Rwandan women, expressed in pg/mg albumin. Plasma AFB1-
albumin levels were quantified using targeted LC-MS (A) in 112 individuals, and (B) 
before and after a trial consuming probiotic L. rhamnosus GR-1 and L. reuteri RC-14 daily 
for 30 days. Concentrations were determined by comparison to 13C-labelled AFB1-lysine 
standard directly injected into samples. No statistical differences were observed between 
day 0 and day 30, according to paired t-test (p>0.05). 
  
  
A B 
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Figure 5.2: Concentration of various mycotoxins in urine of Rwandan women 
Levels of urinary aflatoxins M1, B1/2, and G1/2, fumonisins B1 and B2, ochratoxin A, and 
zearalenone in Rwandan women, expressed in ng/mg creatinine.  
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5.3.2 Association of dietary habits, location, and pregnancy outcomes to 
mycotoxin levels 
Upon stratification of mycotoxin levels by metadata, including dietary habits (vegetable 
and fruit consumption), pregnancy status, history of preterm labour and infertility, and rural 
vs. urban residence, several trends were identified. AFM1 levels were elevated in women 
reporting daily vegetable consumption, compared to those reporting only a few times a 
week (*p<0.05, Figure 5.3). Additionally, plasma AFB1 levels were elevated in pregnant 
women compared to non-pregnant women in this population (**p<0.01, Figure 5.4). 
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Figure 5.3: Urinary aflatoxin M1 concentrations are positively correlated with 
vegetable consumption 
Levels of urinary aflatoxin M1 in Rwandan women, expressed in ng/mg creatinine. 
Vegetable consumption was self-reported in clinical visits upon patient recruitment. 
Significance was determined on log-transformed values using Welch’s two-sample t-test 
with Bonferroni’s multiple test correction (*p<0.05). 
102 
 
 
Figure 5.4: Pregnant Rwandan women have elevated plasma aflatoxin B1 levels 
Levels of plasma albumin-conjugated aflatoxin B1 in Rwandan women, expressed in pg/mg 
albumin. Pregnancy status was reported in clinical visits upon patient recruitment. 
Significance was determined on log-transformed values using Welch’s two-sample t-test 
with Bonferroni’s multiple test correction (**p<0.01). 
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 Discussion 
We report here, using highly reliable and state-of-the-art metabolomics techniques, levels 
of a panel of important fungal toxins in biological samples from Rwandan women. The 
techniques we have used, namely isotopically-labelled spiked standards with solid phase 
extraction, produce accurate results while reducing the effect of matrices on sensitivity 
(292, 293). Signal suppression is typically high for plasma (294) and urine (295) samples. 
Therefore, despite the popularity of dilute-and-shoot methods for urine mycotoxin analysis, 
our methodology was also highly effective, as observed by the large detection percentage 
in our study compared to others (168, 169) and high accuracy and precision (Data not 
shown). Additionally, we have adopted creatinine normalization to adjust for urine 
dilution; however, recent work brings this method into question considering the inter-
individual variation in creatinine excretion (296). To account for this, we also utilized the 
validated 8-colour urine chart for measurement of urine concentration, and found that the 
two were positively related (Figure 5.5). Given this, we are confident in the reliability of 
our measurements. 
Despite numerous studies on mycotoxin contamination in food products and in humans 
from other nations in Africa, no studies have attempted to quantify human exposure to 
mycotoxins in Rwanda. However, the mean of 170 pg AFM1/mg creatinine in this study is 
much in line with that found in cohorts from Ghana and Zimbabwe using similar 
methodology, which ranged from 162–831 pg/mg creatinine (151, 297, 298). Much lower 
concentrations were observed in adults from Cameroon and Kenya, at 40 and 5 pg/mg 
creatinine, respectively (169, 299), despite the latter population having historically been 
highly exposed to AFB1. In contrast to German and Italian populations, for example, where 
exposure risks are much lower, urinary AFM1 was only detectable in 0–6% of the 
population (300, 301). Although urine biomarkers reflect short-term exposure to AFB1, 
chronic exposure can be delineated from plasma AFB1-lysine adducts. We observed 
widespread contamination of AFB1-albumin (mean of 2.2 pg AFB1/mg albumin) in 81% 
of the Rwandan women, demonstrating that reproductive-age women are chronically 
exposed to aflatoxin. In further support of this, there was consistency in the overall level 
of this blood biomarker in a subset of individuals measured again after 30 days. This is 
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consistent with a cohort of Egyptian women, whose serum AFB1-albumin levels were 4.9 
pg/mg albumin (150). One source of AFB1 in this population may be cassava plants, due 
to the observed correlation between vegetable intake and urinary AFM1. Cassava was a 
popularly reported component of their vegetable intake, and it is reported as the most highly 
cultivated crop in Rwanda, with 3,159,551 tonnes being produced in 2014 alone (302). 
Other potential sources that were not indicated in this study include maize and peanuts 
(154, 155), which are frequently colonized by toxigenic Aspergillus spp. 
Interestingly, pregnant women in this cohort had elevated levels of circulating aflatoxin B1 
compared to their non-pregnant counterparts. This could be explained by increased food 
intake because of higher energy demands, since an estimated additional 350 kcal/day and 
500 kcal/day are needed for the second and third trimesters, respectively (303). However, 
since only limited self-reported dietary information was obtained, and pregnancy status 
was not associated with differences in vegetable, fruit, or fish consumption (Data not 
shown), we can only speculate on this association. Furthermore, there is little to no data on 
actual energy intake in pregnant Rwandan women. For example, in an Indian cohort, the 
cumulative increase in calorie intake during the second and third trimesters plateaued at 
approximately 380 kcal/day (304). Regardless, this finding suggests there is an increased 
risk for harm to pregnant women and their developing fetus. 
Fumonisin B2 was present in 21/139 (15%) of samples in this population, much more 
prevalent than FB1 at 3/138 (2%). This is in direct opposition to the consistent trend in the 
literature of FB1 being more abundant than FB2 in food and humans (169, 170). However, 
since toxicological studies in rats and cell culture have concluded that FB1 and FB2 have 
similarly detrimental effects (305, 306), this may not affect clinical outcomes. Regardless, 
research into crops containing fumonisin contamination in Rwanda have either focused 
entirely on FB1 (171), shown consistently higher levels of FB1 than FB2 (156), or not 
detected either (157), leaving many questions unanswered about the source of FB2 in this 
study. Without fully understanding the impact of elevated FB2 in human studies, the 
presently observed concentrations will require further investigation (169, 170, 300).  
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Of the urinary mycotoxins measured, OTA was most commonly detected (71%), and was 
highly elevated at a mean concentration of 684 pg/mg creatinine. This is approximately 10-
fold higher than most other studies measuring OTA in African cohorts (169, 170). 
However, the prevalence of Rwandan staple foods exceeding acceptable values of OTA, 
including peanuts, maize, and cassava (156, 157), are also quite high. OTA is generally 
considered a problem of developed nations due to its prevalence in coffee-based products 
imported from tropical regions and necessity for strict regulations on OTA in stored wheat. 
Nevertheless, OTA-producing Aspergillus spp. have been isolated from Rwandan green 
coffee beans in multiple studies (176, 307). As OTA is known to have nephrotoxic effects, 
it may therefore contribute to the alarming rates of chronic kidney disease in Sub-Saharan 
Africa (308). Given this new information, more research must be done on this toxic 
compound and its biological impact in Rwanda. 
Significant ZEN contamination is prevalent in cassava from Rwanda, with 11.7% of these 
crops containing levels over the regulatory limit (157, 171). It is not surprising, then, that 
ZEN exposure in this population is widespread, contaminating urine at a mean level of 307 
pg/mg creatinine. Similar assessments in Cameroon and South Africa observed comparable 
levels of 210 and 529 pg/mg creatinine, respectively (168, 169). To counteract the 
significant exposure of this population, several studies have focused on utilizing probiotic 
organisms to sequester and detoxify zearalenone. Probiotic Lactobacillus reuteri with 
cloned genes for zearalenone degradation and Bacillus amyloliquefaciens have recently 
been developed with notable success, as they sequester ZEN from absorption and can 
convert it to non-toxic metabolites (309, 310). 
In this study, we have quantified mycotoxins of importance in a novel cohort of 139 
Rwandan women. Aflatoxin, ochratoxin A and zearalenone were widely prevalent in this 
population, with plasma AFB1-albumin disparately affecting pregnant women. Given 
limited dietary information, only aflatoxin B1 could be linked to vegetable consumption. 
However, additional studies will be needed to elucidate the exact source of AFB1 and other 
prevalent toxins, especially OTA. Although no associations were observed between 
mycotoxin concentrations and adverse fertility outcomes, the impact of prolonged 
exposure to these concentrations in reproductive aged women will be important for future 
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work. Given their potential negative consequences on this vulnerable population, 
therapeutics such as probiotics to mitigate exposure to mycotoxins and systematic 
improvements to food safety measures are of utmost importance (311).  
 Materials and Methods 
5.5.1 Human sample collection and ethics 
Recruitment and sample collection of blood and urine from 149 pre-menopausal Rwandan 
women (ages 18–55) was performed at the Central University Hospital of Kigali. Ethics 
approval was obtained under the University of Western Ontario Heath Sciences Research 
Ethics Board (HSREB#102886, Appendix A.2) and the Ethics Committee of Kigali 
University Teaching Hospital (Ref#EC/CHUK/035/12, Appendix A.3). A subset of 30 
women were recruited for a clinical trial of probiotic lactobacilli [urex-cap-5 (RePhresh 
Pro-B), 109 L. rhamnosus GR-1 and L. reuteri RC-14] ingested daily for 30 days, and 
additional samples were collected for these individuals at the end of the trial. First, 
informed consent was read and signed by patients, and a health history questionnaire 
(containing information about fertility, diet, residence, past/present infections, etc.) was 
filled out. Blood collection, including malaria test, was performed by Dr. Stephen Rulisa 
or a registered nurse. Two tubes of blood (3 mL each) were collected from each patient 
into vacutainer tubes. Patients were then instructed to self-collect a urine sample into a 
sterile collection tube. Samples were stored at -80°C, where possible, until processing. 
5.5.2 AFB1-lysine quantification in plasma samples 
Plasma was processed for quantification of albumin-conjugated AFB1 as per the method 
by McMillan et al. (312). Briefly, plasma samples were thawed on ice for 30 min before 
35 μL was aliquoted into a fresh vial for albumin quantification. To precipitate proteins, 
805 μL of 8:2 methanol:water was added to 250 μL of plasma and samples were vortexed 
for 15 sec (313). Following centrifugation at 15 000 rpm for 15 min, supernatant was 
transferred to a fresh vial and stored at -80°C. The protein pellet was resuspended in 230 
μL PBS with agitation using a Teflon pestle. Upon reconstitution, samples were spiked 
with 75 μL of 1.0 ng/mL 13C, 15N-labelled AFB1-lysine standard. To release plasma 
aflatoxin from conjugated albumin, 230 μL of 6.5 mg/mL Pronase® (nuclease-free, Sigma, 
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Oakville, CA) was added to each sample, vortexed for 10 sec, and incubated overnight at 
37°C with agitation at 1300 rpm. Following incubation, 460 μL of MilliQ water was added 
to samples, and subjected to Solid Phase Extraction (SPE) using the Oasis® MAX 1cc 30 
mg extraction cartridge, according to the following established procedure (314). 
Cartridges were activated and equilibrated with two 1 mL aliquots of methanol and MilliQ 
water, respectively. Samples were then loaded at a flow rate of 0.5 mL/min prior to washing 
with 1.0 mL MilliQ water. Impurities were removed using washes with 1.0 mL of 70% 
(v/v) methanol, 1.0 mL of 1% NH4OH in methanol, and 0.5 mL of methanol. Cartridges 
were then dried for 5 min on high, before final elution with 800 μL of 2% formic acid (FA) 
in methanol. Samples were dried using nitrogen gas, then reconstituted in 150 μL of 25% 
methanol and transferred to vial inserts for LC-MS. 
LC-MS analysis was performed using an Easy-nLC 1000 nano-flow system coupled with 
a Q-Exactive Orbitrap mass spectrometer. 10 μL of each sample was injected onto a 
100 μm × 2 cm Acclaim C18 PepMap™ trap column and washed with 20 μL of 0.1% FA. 
Bound compounds were then eluted onto a 75 μm × 15 cm Acclaim C18 PepMap™ 
analytical column (Thermo Scientific, Waltham, US). A flow rate of 300 nL/min was used 
throughout the entirety of the run. The gradient started at 5% B (acetonitrile + 0.1% FA) 
and increased to 35% over 20 min, then increased to 90% B over 2 min and held for 5 min. 
The trap and analytical columns were equilibrated with 6 μL of 0.1% FA in water between 
each run. The injection needle and loop system were washed during analysis with 
isopropanol, acetonitrile:water (50:50) and finally with 0.1% FA in water. The nanospray 
voltage was set at 1.90 kV, capillary temperature 275°C, and S-lens RF level 60. Each 
sample was analyzed by a combination of full MS and parallel reaction monitoring (PRM). 
Full MS was acquired between mass range 150–900 m/z at 35,000 resolution, automatic 
gain control (AGC) target of 5 × 106 and maximum injection time (IT) of 256 ms. PRM 
analysis monitoring the AFB1-Lys and AFB1-
13C6
15N2-L-Lys transitions to m/z 394.1268 
and 400.1413 respectively was accomplished using a 1.0 m/z isolation window, 17,500 
resolution, AGC target 5 × 106 and 25 NCE. Peak areas were integrated in the Xcalibur 
software package at 5 ppm mass accuracy. A calibration curve consisting of seven 
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concentrations of unlabelled AFB1-Lys: 30, 200, 400, 1000, 2000, 3000 and 4000 pg/mL 
each with 500 pg/mL AFB1-
13C6
15N2-Lys was constructed with a linear fit. 
5.5.2.1 Bromocresol purple albumin quantification assay 
Plasma albumin levels were determined using the modified method by Hill & Wells (315). 
To prepare the bromocresol purple (BCP) reagent, 60 µM BCP was dissolved in 0.1 M 
acetate buffer containing 0.15 M sodium chloride and pH brought to 5.5. In a 96-well plate, 
180 μL of BCP reagent was added to 20 μL of 11-fold saline-diluted plasma. Samples were 
processed for 2 min before measuring absorbance at 603 nm. Comparison to a standard 
curve of human albumin at concentrations ranging from 10–60 mg/mL was utilized to 
quantify albumin in each sample. 
5.5.3 Multi-mycotoxin biomarker quantification in urine 
Urine samples were thawed on ice for 30 min, then 200 μL were transferred to a fresh vial 
for creatinine quantification. 5 mL of each urine sample was diluted 1:1 with deionized 
water and centrifuged at 4500 × g for 10 min to remove solid matter. Supernatants were 
then transferred to fresh containers and set to pH 7.0 with ammonium hydroxide and formic 
acid. Samples were then spiked with 10 μL of a working solution containing 13C, 15N-
labelled internal standards at the following concentrations: 60 ng/mL aflatoxin M1, 12 
ng/mL fumonisin B1, 30 ng/mL fumonisin B2, and 30 ng/mL ochratoxin A. Quantification 
of aflatoxins B1, B2, G1, G2, and zearalenone were also performed by comparison to 
standard curves run with each batch. Diluted urine was run through SPE using the Oasis 
Max 6cc 150 mg extraction cartridge, according to the following procedure. 
Cartridges were activated and equilibrated with two 5 mL aliquots each of methanol and 
deionized water, in that order. Samples were then loaded at a flow rate of 0.5 mL/min and 
rinsed with 5.0 mL deionized water. Each column was eluted with 3 mL of 100% methanol 
and collected for analysis of aflatoxins and zearalenone. Columns were then washed with 
2 mL each of 5% (v/v) NH4OH in methanol, 100% methanol, and 2% formic acid in 25% 
methanol. Cartridges were then dried for 5 min on high, before final elution with 5× 750 
μL of 2% formic acid in methanol. Both collected fractions were dried using nitrogen gas, 
109 
 
then reconstituted in 250 μL of 25% methanol with agitation at 4500 × g and transferred to 
LC-MS vials. 
Reconstituted urine samples were analyzed using an Agilent 1290 Infinity HPLC coupled 
to a Q-Exactive Orbitrap mass spectrometer (Thermo) with a HESI (heated electrospray 
ionization) source. For HPLC, 10 μL of each sample was injected into a ZORBAX Eclipse 
plus RRHD C18 (2.1 × 50 mm × 1.8 µm) column, maintained at 35°C using a flow rate of 
0.3 mL/min. Mobile phase (A) consisted of 0.1% formic acid in LC-MS grade water and 
mobile phase (B) consisted of 0.1% formic acid in acetonitrile. The initial composition of 
0% (B) was held constant for 0.5 min, then increased to 100% over 3.0 min. Mobile phase 
B was then held at 100% for 2.0 min, then returned to 0% over 0.5 min for a total run time 
of 6.0 min.  
The HESI source was operated under the following conditions: nitrogen flow of 17 and 8 
arbitrary units for the sheath and auxiliary gas respectively, probe temperature and capillary 
temperature of 450°C and 400°C respectively, S-Lens RF level of 45, and capillary voltage 
of 3.9 kV. Targeted analytes and internal standards were monitored by LC-MS/MS 
acquisition mode using the following settings: 1.2 m/z isolation window, normalized 
collision energy of 35, resolution of 17 500, AGC target 5 × 106, and maximum injection 
time of 110 ms. Standard curves were run with every batch to account for sample variation, 
or absolute quantification was performed by isotope dilution method. The target analytes 
were monitored by MS/MS using the conditions shown in Table 5.2. Aflatoxins and ZEN 
were measured in SPE fractions collected from the initial 100% methanol elution, while 
fumonisins and OTA were measured in SPE fractions collected from the final 2% FA in 
methanol elution. 
Table 5.2: Tandem-MS conditions for urine mycotoxin analytes 
Name Formula Precursor m/z Product ion m/z NCE 
AFM1-labelled C17H12O7 346.12 288.12561 40 
AFM1 C17H12O7 329.07 273.07523 43 
AFB1 C17H12O6 313.07 241.04924 57 
AFB2 C17H14O6 315.09 259.05991 59 
AFG1 C17H12O7 329.07 243.05945 43 
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AFG2 C17H14O7 331.08 245.08093 60 
FB1-labelled C34H59NO15 756.51 356.38370 29 
FB1 C34H59NO15 722.40 352.32092 29 
FB2-labelled C34H59NO14 740.51 358.39935 27 
FB2 C34H59NO14 706.40 336.32574 27 
OTA-labelled C20H18ClNO6 424.16 268.05771 22 
OTA C20H18ClNO6 404.09 257.02087 22 
ZEN C18H22O5 319.15 187.07556 32 
For absolute and relative quantification of mycotoxins of interest, seven-dilution 
calibration curves were created consisting of: Unlabelled AFM1 (0.023, 0.046, 0.23, 0.46, 
2.3, 4.6, and 23 ng/mL) each with 1.2 ng/mL labelled AFM1; unlabelled AFB1 and AFG1 
(0.046, 0.092, 0.46, 0.92, 4.6, 9.2, and 46 ng/mL); unlabelled AFB2 and AFG2 (0.0115, 
0.023, 0.115, 0.23, 1.15, 2.3, and 11.5 ng/mL); unlabelled FB1 (1.15, 2.3, 11.5, 23, 115, 
230, and 1150 ng/mL) each with 6 ng/mL labelled FB1; and unlabelled FB2, OTA, and 
ZEN (0.46, 0.92, 4.6, 9.2, 46, 92, and 460 ng/mL) each with 6 ng/mL labelled FB2 and 
labelled OTA. Following data acquisition, peak areas were quantified using the Xcalibur 
software package. Peaks were identified within a retention time window and width of 0.5 
and 0.75 min respectively, at 50 ppm mass accuracy. Peak detection and integration using 
the Genesis method was performed, with a signal-to-noise threshold of 0.5 and signal-to-
noise minimum peak height of 3.0 respectively. Automatic processing was supplemented 
with manual confirmation of peaks. 
5.5.3.1 Measurement of additional urine characteristics 
Urine creatinine levels were measured using the Creatinine (urinary) Colorimetric Assay 
Kit (Cayman Chemical Co., Ann Arbor, MI, USA), according to the manufacturer’s 
instructions. Urine hydration status was graded according to the validated 8-scale urine 
colour chart originally developed by Armstrong et al. (316, 317). Creatinine concentrations 
were plotted against urine colour in Figure 5.5. pH was measured following 1:1 dilution 
of urine with milli-Q water, and additional characteristics such as cloudiness and presence 
of blood were recorded. 
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Figure 5.5: Urine colour and creatinine concentration are positively related 
Interquartile ranges of creatinine concentration stratified by urine colour, with outliers 
individually plotted. Colour was determined according to the 8-scale chart and creatinine 
was quantified using a creatinine (urinary) colorimetric assay kit. Line indicates mean 
creatinine level for each group. 
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5.5.4 Data processing and statistical analysis 
Following peak detection, concentrations (in ng/mL) were calculated based on calibration 
curves for each mycotoxin. Values were excluded from additional analyses if below the 
limit of quantification. Plasma AFB1 levels were normalized to serum albumin, while all 
urine mycotoxins were normalized to creatinine to account for variation in dilution of these 
fluids. All concentrations were log-transformed prior to statistical analysis to obtain normal 
distribution. Associations between mycotoxin levels and patient metadata were performed 
in R (r-project.org), accounting for multiple test correction. All graphing was done using 
GraphPad Prism 6 (La Jolla, CA). 
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Chapter 6  
 
General Discussion and Conclusions 
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 Discussion 
This thesis has provided a series of studies that have increased our understanding of 
microbes, particularly their influence on women’s health. Lactobacilli in the vaginal 
microbiota are known to play a large part in preventing dysbiosis and infection by sexually 
transmitted diseases. Interventions to increase their abundance and production of beneficial 
lactate have been sparse until now. Furthermore, surprisingly little is still known about the 
role of the most predominant carbon source in the vagina—glycogen—on the vaginal 
microbiota. While much of this research has focused on issues predominantly affecting 
women in North America and Europe, there is a current lack of research on the effects of 
infectious microbes on women’s health in the developing world. An ongoing problem is 
chronic exposure to fungal toxins, which are found ubiquitously in crops from countries in 
Africa, and which have a range of effects on infertility, pregnancy outcomes, and women’s 
health, in general. Therefore, this thesis has expanded knowledge of exogenous and 
endogenous carbohydrates on the composition and activity of vaginal microbes, and the 
extent and impact of mycotoxin exposure in a group of high-risk women in Rwanda. 
6.1.1 Lactulose supports vaginal acidity and maintenance of a Lactobacillus-
dominated microbiota 
In Chapter 2, I evaluated the potential of lactulose, against three other common prebiotics, 
to selectively stimulate vaginal lactobacilli without also propagating BV organisms or C. 
albicans. Lactulose was fermented by a broad array of common vaginal lactobacilli, 
namely L. iners and 16 L. crispatus isolates, while not influencing the growth of G. 
vaginalis, A. vaginae, P. bivia, or M. curtisii (Figure 2.1–2.3). However, the use of single 
cultures does not represent the diversity present in the vagina. As the current animal models 
for BV also only utilize single organism inoculation (182), I developed a batch culturing 
method using swabs taken directly from healthy or BV-affected women. Using this 
polymicrobial model, challenging with lactulose restored acidic pH and increased lactic 
acid production in both healthy and BV communities, and attenuated odor-associated 
amine secretion in the dysbiotic model (Figures 2.7, 2.11, and 2.12). Although lactulose 
treatment helped to maintain a Lactobacillus-dominated community in the healthy system, 
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the few remaining lactobacilli could not be stimulated in the BV model to restore a healthy 
profile (Figures 2.4, 2.5, 2.9, and 2.10). 
In Chapter 3, I demonstrated direct antagonism of lactulose-stimulated L. crispatus 
products against BV organisms, which was dependent on acidic pH (Figure 3.1). Unlike 
other carbohydrate-based interventions, lactulose supplementation does not interfere with 
L. crispatus adherence (Figure 3.2), an important commensal property of this bacterium 
(76). This supports a mechanism whereby this beneficial organism ferments lactulose into 
abundant lactic acid, creating a hostile environment for acid-labile microbes. However, 
caution must be taken should future extensions of this research arise, as lactulose 
detrimentally affects the viability of vaginal epithelial cells (Figure 3.3). 
As an extension to these promising findings, lactulose must be evaluated further in a 
randomized controlled clinical trial for the maintenance of a healthy vaginal microbiota. 
Given the high incidence of periodic fluctuations from homeostasis to dysbiosis during the 
menstrual cycle and in pregnancy (39, 318), a therapeutic that supports microbial eubiosis 
would be clinically useful. Furthermore, there is promise for lactulose in conjunction with 
treatments known to stimulate Lactobacillus spp., such as probiotic GR-1 and RC-14 (131), 
in a two-pronged synbiotic approach that takes advantage of the metabolic benefits of 
lactulose. This research has direct application for use in women, and is worth continuing 
to potentially reduce the burden of antibiotic use in BV. Additionally, the polymicrobial 
batch culture model developed in this thesis will be valuable for future research evaluating 
vaginal prebiotics or other microbiota interventions, as it more closely resembles the 
diversity present in vivo. 
6.1.2 Glycogen utilization by BV organisms and Lactobacillus iners is self-
limiting 
Much of the previous work evaluating the role of glycogen in shaping the vaginal 
microbiota relied on retrospective correlations to healthy women. With the work done in 
Chapter 4 of this thesis, glycogen metabolism was directly observed by BV-associated G. 
vaginalis, A. vaginae, P. bivia and M. curtisii, as well as the first report of its utilization by 
vaginal lactobacilli—L. iners (Figures 4.1–4.4). Interestingly, acidic metabolites produced 
116 
 
in this degradation process by L. iners and G. vaginalis had a self-killing effect, but also 
antagonized other dysbiotic members of the vaginal microbiota (Figures 4.5–4.6). 
Secretions from L. iners treated with glycogen remained antagonistic to G. vaginalis upon 
neutralization (Figure 4.5), suggesting a metabolite was produced that either prevented 
glycogen utilization by G. vaginalis or was bacteriostatic. These findings emphasize that 
the widely stated reason that lactobacilli propagate in the vagina because of glycogen, is 
misleading at best. 
Others have reported lactic acid to be inhibitory to α-amylases (262), enzymes known to 
catabolize glycogen. However, lactic acid at the same concentration as was present in L. 
iners supernatants had no effect on G. vaginalis or L. iners growth in glycogen (Figure 
4.7). Furthermore, the remaining inhibitory effect was not due to nutrient depletion because 
neutralized, spent supernatants from G. vaginalis did not similarly prevent L. iners growth 
in glycogen (Figure 4.6). Therefore, despite an attempt to characterize the nature of this 
substance, it remains elusive. 
A rational next step will be to perform metabolomic analysis on these supernatants to 
examine compounds secreted by L. iners upon glycogen metabolism for their inhibition of 
other organisms. This could be combined with an examination of the L. iners genome for 
candidate molecules, albeit none have been found so far (47). Future work should also aim 
to characterize genes for glycogen metabolism in a broader profile of vaginal organisms, 
not just in L. iners isolates, to determine how conserved this phenotype is. With this 
information, targeted inhibition of these enzymes may be possible as an intervention to 
limit the nutrient availability of organisms associated with dysbiosis. As there are feminine 
health products already integrating glycogen under the pretense that it will beneficially 
modify the vaginal microbiota, it is essential that research be done to understand its true 
impact in this system. The work in this thesis provides support against its exogenous 
administration due to the potential to stimulate BV organisms. 
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6.1.3 Rwandan women are significantly exposed to aflatoxins, fumonisins, 
ochratoxin A, and zearalenone 
In Chapter 5 of this thesis, I developed a method and measured the biological exposure of 
139 Rwandan women to a panel of fungal toxins with worldwide importance: Aflatoxin 
B1, fumonisin B1 and B2, ochratoxin A and zearalenone. Aflatoxins were found to be 
widely present in this population. Indeed, 81% and 49% of women had detectable levels of 
AFB1-albumin and AFM1, respectively, the two major biomarkers for AFB1 exposure in 
blood and urine (290, 291). Since AFM1 in urine was positively correlated to vegetable 
intake, I posited that widely popular crops known to be contaminated with aflatoxins, such 
as cassava (154, 157), could be the source. Increased long-term aflatoxin exposure was 
observed in pregnant compared to non-pregnant Rwandan women, which raises serious 
concern over the health of mothers and their developing fetuses. 
Urinary levels of ochratoxin A and zearalenone were also surprisingly high, with mean 
concentrations of 684 and 307 pg/mg creatinine in the 71% and 51% of women that had 
detectable levels, respectively. Fortunately, higher levels of these mycotoxins were not 
associated with adverse fertility outcomes, as determined by comparison to patient 
metadata. However, without knowing the source and extent of this contamination in the 
entire population, the impact of these elevated levels remains unknown. Regardless, 
reporting of ochratoxin A challenges the notion that it is not a frequent contaminant in 
African nations, and provides rationale to continue studying its influence in the developing 
world. Fumonisins B1 and B2 were less extensively detected, with only 2% and 15% of 
women having quantifiable levels. 
Extending this research to larger populations in Rwanda with carefully collected dietary 
information would be beneficial to understanding the widespread impact and food source 
of the contamination. Given the known negative consequences of mycotoxin exposure, 
therapeutics such as probiotics that might mitigate exposure to, and absorption of, 
mycotoxins (309, 310) and systematic improvements to food safety measures are of utmost 
importance. Women in Africa are disparately affected by crop-related toxins due to their 
dominance in the farming workforce and in meal preparation (183), so studies focused on 
the impact on women are essential. This thesis provides a quantification of mycotoxin 
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levels in reproductive-age Rwandan women, which were previously unreported, and 
provides insight into some possible sources of aflatoxin B1 and the elevated risk for 
pregnant women. 
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